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Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a tumor predisposition
syndrome caused by heterozygous germline mutations in a nuclear gene encoding
fumarate hydratase (FH), an enzyme of the mitochondrial tricarboxylic acid cycle (TCA
cycle). The syndrome is characterized by cutaneous (CLM) and uterine (ULM)
leiomyomas, and renal cell cancer (RCC). Moreover, a few cases of the malignant
counterpart of ULM, uterine leiomyosarcoma (ULMS) have been reported in the Finnish
HLRCC population. To date, over 130 HLRCC families have been identified throughout
the world, but the families with RCC are mainly from North America and Finland.
Homozygous germline mutations in FH predispose to a severe neurological defect called
FH deficiency (FHD). Another tumor predisposition syndrome, hereditary
paragangliomatosis (HPGL), is caused by inherited mutations in the genes encoding
subunits of succinate dehydrogenase (SDHB/C/D), also an enzyme of the TCA cycle as
well as of the mitochondrial electron transport chain. HPGL is associated with
paragangliomas and pheochromocytomas. The biallelic inactivation of FH and SDH in
the associated tumors suggests that they operate as tumor suppressor genes. As a
consequence of a defective TCA cycle, tumors in these syndromes display an abnormally
activated hypoxia-inducible factor 1 (HIF1) pathway causing a stage of
“pseudohypoxia”. HIF1 is a transcription factor which is normally activated by hypoxia.
It drives transcription of genes encoding e.g. angiogenetic and glycolytic factors to
promote cells’ survival in low oxygen tension but which can also facilitate tumor growth.
Recently it has been suggested that hypoxia and HIF1 could be one of the causes of
genetic instability, typical for many tumors.
The penetrance of malignant tumors in HLRCC is reduced, and thus the association of
other malignancies which are less central for the phenotype may have remained
unidentified. Moreover, the actual risk of cancer in the FH mutation-positive families has
not been determined. To clarify these clinical features of FH mutation-associated tumor
predisposition, genealogical and cancer data was extensively collected from members of
eight Finnish FH mutation-positive families, including one FHD family. Altogether 868
individuals were identified. Risk of cancer was determined with the standardized
incidence ratio by comparing the number of cancer cases in HLRCC/FHD families with
those in the general population. This Finnish Cancer Registry-based analysis revealed
increased incidence for RCC (6.5-fold), and for ULMS as defined prior to 2003 (71-fold).
In young individuals the risk was even more pronounced. However, many of the ULMSs
in the series do not fulfill the most recent and more stringent ULMS diagnosis criteria,
but can now be classified as atypical or proliferative ULMs (with a low risk of
recurrence). Hence, the risk for ULMS - as defined at present - appears to be lower in
HLRCC than originally calculated. The analyses of biallelic inactivation of FH in
HLRCC/FHD patients’ tumors suggested possible association of breast and bladder
cancer with the loss of FH, though increased incidence of these tumors was not observed
in the Cancer Registry risk analysis. In the present study, cancer cases were for the first
time detected also in the FHD family.
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Typically RCCs in HLRCC are unilateral and display papillary type 2 histology.
Occasionally collecting duct carcinomas are also found. A novel type of RCC histology
appeared in a young Spanish HLRCC patient case included in this study. The other
tumor of this patient’s bilateral renal lesions was a conventional (clear cell) type which is
distinct from the types previously observed in HLRCC. This discovery suggests FH
mutation carriers may exist also among young patients with conventional RCC.
Since tumors from FH and SDHB/C/D mutation carriers display pseudohypoxia
associated with stabilized HIF1  (a subunit of HIF1), the recent hypothesis on the link
between HIF1/hypoxia and genetic instability was of interest to study in HLRCC and
HPGL tumor material. HIF1  stabilization was confirmed with immunohistochemistry
to be present in the majority of the studied specimens. However, no repression of MSH2,
a protein involved in mismatch repair of DNA, or microsatellite instability (MSI), an
indicator of genetic instability, was observed. The findings show that the suggested
instability pathway is not activated by pseudohypoxia at least in TCA cycle-deficient
tumors.
Recently, a novel FH transcript was described in a sequence database. To study putative
alternative functions of FH, the variant FH transcript (FHv) was further characterized.
When amplified in full length, FHv was found to contain exons 2-10 identical to FH and
an alternative exon 1b. Thus, FHv lacked the exon 1 encoding the mitochondrial
targeting signal. Overexpression analyses showed that localization of FHv was nuclear
and cytoplasmic and it was devoid of FH enzyme activity. Moreover, exon 1b was found
to be the 5’ untranslated region. FHv mRNA was ubiquitously expressed in human
tissues but at a level hundreds of times lower than FH. Subsequently, the endogenous
protein could not be reliably confirmed. Interestingly, FHv mRNA expression was
significantly increased in cell lines treated with hypoxic and heat stress, indicating its
possible role in stress-induced apoptosis or survival in unfavorable conditions.
However, the function of FHv remains elusive.
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1. INTRODUCTION
Any human can contract a cancer or benign neoplasm, but an inherited germline
mutation in a certain set of genes can make an individual more susceptible to tumor
formation. Thus, a mutant allele in a susceptibility gene causes an increased risk of
tumors (benign or malignant). The degree of the risk is influenced by the particular gene
and mutation, and other genetic, lifestyle, and environmental factors (Fearon, 1997). The
key indicators of tumor heritability include several affected members in a family, young
age at tumor onset, tumors arising at multiple sites, and existence of multifocal or
bilateral lesions (Greco & Mahon, 2004). Hence, the features of the patient affected by a
tumor and the family history are signs that a conscious clinician can utilize in linking the
disease to a possible genetic inheritance. To date many susceptibility genes have already
been identified, but still some unexplained familial risk of tumor formation exists. The
identification of susceptibility genes, and subsequently of the individuals at risk, is an
important task considering patient surveillance, possible prevention, and early detection
and treatment of a tumor, especially in the case of predisposition to malignancy.
Importantly, personal and social pressures followed by knowledge on inherited risk
have to be taken into account in predictive testing and genetic counseling (Offit & Thom,
2007).
Although out of all cancer cases only approximately 5-10% is due to an inherited
predisposition, the identification of hereditary syndromes has in fact played a significant
role in cancer research since the susceptibility genes can be mutated in sporadic tumors
as well (Knudson, 2002). However, in order to understand the mechanism by which a
mutation in a certain gene leads to tumorigenesis, it is essential to determine the protein
product’s function and the molecular pathway or pathways where it operates. In
general, the tumorigenesis-associated proteins take part in the processes which regulate
cell growth, differentiation, or death (Vogelstein & Kinzler, 2004). Finally, knowledge
about the function of the “tumor protein” and its interactions with other molecules may
provide opportunities to identify possible therapeutic agents.
This work focuses on two rare, recently identified tumor predisposition syndromes,
hereditary leiomyomatosis and renal cell cancer (HLRCC) and hereditary
paragangliomatosis (HPGL), both of which are characterized by benign and malignant
tumors. The susceptibility genes of these syndromes encode proteins of a known
function, fumarate hydratase (FH) and succinate dehydrogenase (SDH), respectively, but
their contribution to tumorigenesis has not been completely determined. This work has
therefore aimed to clarify the molecular pathways in which FH and SDH participate.
Since the phenotype of HLRCC is variable, especially related to the penetrance of the
malignant tumor types, it was also intended to broaden the clinical definers of the
syndrome.
Medical research often requires material from patients, e.g. tumor tissue or blood for
DNA extraction. The ethical aspects of human experimentation, including the use of
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human tissue material, are regulated by national laws and international declarations
such as the Declaration of Helsinki. The main ethical principle in medical research is that
the patient’s participation in a study is based on an informed decision and consent and
that the patient always takes precedence over the interests of science and society.
Accordingly, the study presented here was approved by the Helsinki University Central
Hospital authorized ethics review committee and all the samples were taken only after
obtaining each individual’s informed consent or authorization from the National
Authority for Medicolegal Affairs.
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2. REVIEW OF THE LITERATURE
2.1. Etiology of cancer
2.1.1. Cancer genetics
Cancer includes a variety of different physiological conditions, but the genetic origin of
this disease can be used to define its essence. Although many environmental and
lifestyle factors as well as viral infections play a role in the genesis of cancer, an
aberration in the genetic material is the basal cause or main contributor to the malignant
transformation of a cell. The genetic aberrations include changes at the chromosomal
level (translocations, whole chromosome arm or chromosome amplifications or
deletions), and at the nucleotide level (major and minor amplifications and deletions,
and nucleotide substitutions) (Jones & Baylin, 2007). Moreover, epigenetic changes
which do not alter the actual DNA sequence can modify DNA. These changes include
abnormal chromatin remodeling or methylation, including gene activation by promoter
hypomethylation and inactivation by hypermethylation (Feinberg, 2007).
The genes, which in mutated form contribute to tumorigenesis, can basically be grouped
by type; oncogenes, tumor suppressor genes (TSG), and DNA repair genes. Mutations in
oncogenes usually result in the hyperactivation of the gene or activation of it in
abnormal conditions. The oncogenes with their normal activity are also called as proto-
oncogenes. In contrast to the gain of function of oncogenes, TSGs lose their function
when mutated. Usually the function of TSG is lost only when both the alleles are
inactivated (Vogelstein & Kinzler, 2004). However, the tumorigenic effect in the case of
haploinsufficient TSGs is attained already by the inactivation of the other allele only
(Cook & McCaw, 2000). The DNA repair genes, also termed caretakers, include genes
encoding proteins that take care of mismatch repair (MMR), nucleotide excision repair
(NER), and base-excision repair (BER). In addition to these subtle error repairing
processes, control mechanisms attending to a larger DNA material, for example in the
mitotic recombination and chromosomal segregation, can be repressed in cancer cells
(Vogelstein & Kinzler, 2004, see also 2.1.2.3). The nature of repair genes is similar to the
classic TSGs as both the alleles of these genes usually have to be inactivated to have a
physiologic effect, even if some functional defects in the repair system have also been
detected in non-neoplastic cells of heterozygous MMR mutation carriers (Alazzouzi et
al., 2005).
At present, the number of genes involved in tumorigenesis is estimated at approximately
one percent of all human genes (Futreal, 2004). A tumorigenesis associated genetic
alteration may occur in a somatic cell or can be present in each cell of an individual due
to an inherited germline mutation; the latter resulting in a hereditable tumor
predisposition. To date, approximately 30 different high-penetrance genes are linked to
hereditary cancer, of which a few are oncogenes and DNA repair genes, but most of
them are TSGs. Often, but not always, the same genes are found to underlie the genesis
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of corresponding sporadic tumors as well (Knudson, 2002). An explanation for familial
clustering of tumors cannot, however always be found from the known genes. The
unexplained familial risk can be partly understood by the as yet unidentified high-
penetrance (high-risk) cancer genes, but evidence on the association of low-penetrance
(low-risk) susceptibility allele variants in cancer predisposition has increasingly emerged
(Houlston & Peto, 2004).
2.1.2. Cancer pathways
Depending on the tumor type, accumulation of a variable number of genetic alterations
in the cancer genes finally leads to the malignant transformation of a cell and the
formation of cancer. The process may occur in the cells of normal tissue but cancer can
also generate from a pre-existing benign lesion. The capabilities that a transforming cell
attains from the mutations may be summarized as the six hallmarks of cancer, as
introduced by Hanahan and Weinberg: 1) limitless replicative potential, 2) self-
sufficiency in growth signals, 3) insensitivity to anti-growth factors, 4) sustained
angiogenesis, 5) evading apoptosis, and 6) capability of tissue invasion and metastasis
(Hanahan & Weinberg, 2000). Genetic instability has been considered as one of the
common hallmarks of cancer cells as well, though the requirement of increased mutation
rate to acquire the sufficient number of pathogenic mutations for cancer formation has
not been established (Tomlinson et al., 1996). Although the number of pathways
associated with these characteristics is limited, they are complexly regulated and thus
the number of genes as mutational targets is high. In the following sections some of the
pathways and some of the key players in the cellular events related to cancer are
presented.
2.1.2.1. Examples of aberrant signaling pathways in cancer
RB PATHWAY: Stated simply, activation of oncogenes and inactivation of TSGs stimulates
the cell birth (cell cycle) and maintenance, or inhibit the cell cycle arrest and apoptosis. A
well-known tumor suppressor, RB (retinoblastoma protein), operates in a number of
processes that are linked to cancer including the cell cycle. Indeed, one of the main
pathways of cell cycle regulation involved in cancer is the p16INK4a - cyclinD-CDK4 - RB
pathway. In the cell cycle, the regulation of the transition from the resting stage (G0 or
G1) to the synthesis (S) phase is particularly important. In the “RB pathway”, RB acts as
a transcriptional inhibitor of genes that are required for DNA synthesis. RB function can,
however, be disrupted for example by mutational inactivation or phosphorylation by
cyclinD-dependent kinases. Cyclin-dependent kinases (CDK) are mediators of cell cycle
transitions along with their regulatory cyclin subunits (including types D and E).
CyclinD-dependent kinases normally act only in response to mitogens, but when over-
expressed (e.g. through amplification) they abnormally repress RB’s growth-inhibiting
function leading to uncontrolled enter to active cell cycle and increased proliferation.
Moreover, loss of p16INK4a, an inhibitor of cyclinD-dependent kinases, leads to a similar
RB repressive effect (Sherr, 2000, Classon & Harlow, 2002).
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In addition to the ability to block the cell cycle S-phase, RB has a variety of other
functions. It is believed to regulate differentiation, responses to DNA damage and
provide protection against apoptosis. The tumor suppressing mechanisms of RB are not
fully characterized but alterations in these functions may also be involved in
tumorigenesis (Classon & Harlow, 2002). The importance of RB emerged already in 1971,
when the comparison studies on the kinetics of retinoblastoma eye tumor formation in
familial and sporadic cases established the basis for the requirement of biallelic
inactivation of TSGs. (Knudson, 1971). Moreover, RB was the first cloned TSG. At
present it is estimated that almost all human cancers display defective RB function,
either caused by RB mutations, blockade of RB by certain viral proteins, or alterations in
its upstream regulators (Weinberg, 1995).
p53 PATHWAY: To maintain genetic integrity, mutations in the DNA are aimed to be
corrected by the cellular repair mechanisms, and if a cell has undergone irremediable
errors, it is normally programmed to die. These processes are regulated by another
important tumor suppressor, p53. When a cell is under normal physiological conditions,
p53 seems to have very little implication, but when disturbed by the abnormal activation
of oncogenes, DNA damage, chromosomal aberrations, and hypoxia among others, p53
becomes active. The p53 response, i.e. triggering pathways that take care of the damage
or eliminate the faulty cell, prevents the expansion of cells with a malignant potential
(Oren, 2003). The regulatory effects of normal p53 comprise the transcriptional activation
of its target genes and inactivation of antiapoptotic genes, as well as of other,
transcription-independent activities (Oren, 2003). For example, p53 operates in a cell
cycle regulatory pathway with ARF and MDM2. The tumor suppressor ARF (p14ARF),
which is able to recruit the growth arrest- or apoptosis-inducing p53, operates in the
downstream of RB. ARF is activated by abnormal mitogenic signals, such as over-
expression of oncoproteins c-MYC, RAS, and E2F1. The illegitimate signaling cascades
are blocked by ARF as it antagonizes MDM2, the negative regulator of p53. Hence, this
pathway may be disrupted by inactivating mutations in p53 and ARF, or aberrant
activation of MDM2 (Sherr, 2000).
Naturally, several other factors also play a role in the cell proliferation and apoptosis
signaling system. For example, members of the B-cell lymphoma 2 family (BCL2) (e.g.
the antiapoptotic BCL2 and one of the target genes of p53, the proapoptotic BAX) under
stress conditions “decide” whether to initiate the apoptosis program (e.g. activation of
caspases) or not (Cerroni & Kerl et al., 1994, Yin et a., 1997, Adams, 2003). p53 itself is
somatically mutated in approximately half of all human cancers and many more display
another genetic alteration leading to the repression of p53 mediated pathways (Royds &
Iacopetta, 2006). However, it is notable that in certain mutant forms, p53 not only loses
its tumor suppressing capabilities, but has also been shown to gain some oncogenic
properties (Kastan & Berkovich, 2007). Inherited mutations in p53 cause LI-FRAUMENI
syndrome which is characterized by a large spectrum of early-onset tumors (Royds &
Iacopetta, 2006).
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RTK (AKT-mTOR) PATHWAY: Mediating growth-promoting extracellular signals to the
cellular machineries is one event linked to cancer. Receptor tyrosine kinases (RTKs) are
type I transmembrane proteins, of which cytoplasmic domain’s catalytic activity is
switched on upon a ligand binding (Hunter, 2000). For example, this signaling cascade
can be abnormally activated by mutations in oncogenes encoding RTKs, such as KIT, c-
MET, RET, and ERBB2 in gastrointestinal stromal tumors (GIST), kidney, thyroid, and
breast and ovarian cancer, respectively (Vogelstein & Kinzler, 2004). RTK activation by a
growth factor or by an activating mutation leads to induction of downstream signal-
transduction elements such as the oncoproteins GTPase RAS and the lipid kinase
phospoinositide 3-kinase (PI3K). Subsequently, the activating signal is mediated, for
example, to the oncogenic mitogen-activated protein kinase (MAPK) or AKT (PKB)
family of threonine/serine kinases. In close association with the AKT (and also MAPK)
pathway is the threonine/serine kinase mTOR (mammalian target of rapamycin)
pathway which is negatively regulated by the complex of the tumor suppressors tuberin
(TSC2) and hamartin (TSC1). Active AKT in turn operates as an inhibitor of TSC2 (Shaw
& Cantley, 2006). Hence, in addition to the mutational activation of RTKs, also
inactivating mutations in TSC1, TSC2, and PTEN (the antagonist of PI3K function), or an
activating mutation in RAS leads to hyperactivation of the AKT-mTOR pathway. TSC1,
TSC2, and PTEN, among some other genes, are linked e.g. to a group of familial neuro-
cutaneous disorders (phakomatoses) (see also 2.2.2). In general, the AKT-mTOR pathway
is associated with increased growth, resistance to apoptosis, and cellular metabolism
(Hay, 2005).
TGF-  PATHWAY: Signal transduction through the cell membrane is mediated also by
transmembrane threonine/serine kinases, such as transforming growth factor  (TGF- )
receptors 1 and 2 (TGF- R1, TGF- R2), which are activated by TGF-  cytokines. These
signals activate SMAD proteins which are subsequently translocated to the nucleus
leading to activation and repression of hundreds of genes related to diverse cellular
processes such as proliferation, invasion, metastasis, apoptosis, immune surveillance,
and angiogenesis (Kang at al., 2003, Shi & Massague, 2003, Jakolew, 2006). Because TGF-
 generally has a negative effect on cell growth, repression of the TGF-  - SMAD
pathway contributes to tumorigenesis (Shi & Massague, 2003). For example, inactivation
of TGF- R1, TGF- R2 and SMAD4 has been associated with colorectal and ovarian
cancer as well as hereditary JUVENILE POLYPOSIS (JP), respectively (Jakolew, 2006).
WNT PATHWAY: Wnt signaling cascade promotes the expression of genes affecting, for
example, proliferation, differentiation, and invasion, such as c-MYC, cyclinD1 (CCND1),
and MMP7, respectively. The Wnt pathway is especially stimulated in colorectal cancer
(CRC) for example by activating mutations in -catenin which after association with the
T-cell factor/lymphoid enhancing factor (TCF/LEF) operates as the transcription activator
of the above mentioned target genes. However, the majority of sporadic CRCs as well as
patients with FAMILIAL ADENOMATOUS POLYPOSIS (FAP) harbor inactivating mutations in
the tumor suppressor adenomatous polyposis coli (APC) which is part of the -catenin
degradation complex. APC mutations have been suggested to cause chromosomal
instability (CIN) as well (Giles et al., 2003).
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2.1.2.2. Hypoxia-inducible factor 1 (HIF1)
Some cancer-associated proteins take part in several pathways and create a cross-talk
between them. It appears that many TSG and oncogene pathways are linked directly or
indirectly to the HIF1 pathway (Vogelstein & Kinzler, 2004). The hypoxia-inducible
factor 1 (HIF1) is the master regulator of oxygen homeostasis and it has been shown to
drive transcription of up to 100 cell type-specific target genes (Semenza, 2003, Kim &
Kaelin, 2006). The HIF1 heterodimer is comprised of HIF1  (ARNT) and HIF1  subunits,
the latter one being highly regulated. The synthesis of HIF1  is induced mainly by
growth factor signals through PI3K and MAPK pathways (Fukuda et al., 2002) (Table 1).
In normoxic conditions, the HIF1 function is, however, inhibited by targeting HIF1
protein to degradation. Oxygen-dependent prolyl hydroxylase-domain proteins
(PHD1/EGLN2, PHD2/EGLN1, and PHD3/EGLN3) hydroxylate Pro-402 and Pro-564 of
HIF1  for von Hippel Lindau protein (pVHL) recognition. pVHL is a component of the
E3 ubiquitin-protein ligase complex along with elongin B, elongin C, Cullin 2, and Rbx1.
Ubiquitylated HIF1  is subsequently degraded by the proteasome (Maxwell et al., 1999).
HIF1  is also regulated in an oxygen-dependent manner by factor-inhibiting HIF1
(FIH1), which prevents HIF1  interaction with its co-activators p300 and CBP (Mahon et
al., 2001, Hewitson et al., 2002, Lando et al., 2002a & 2002b). As HIF1 responds to
lowered oxygen (by becoming stabilized and associated with its co-activators), the genes
that are activated through HIF1 binding to the target sequence (hypoxia response
element, HRE) encode most of all angiogenic factors (e.g. vascular endothelial growth
factor, VEGF), glucose transporters (e.g. glucose transporter 1, GLUT1), glycolytic
enzymes (e.g. lactate dehydrogenase A, LDHA), survival factors (e.g. transforming
growth factor , TGF ), and invasion factors (e.g. matrix metalloproteinase 2, MMP2),
among others (Semenza, 2003).
Another oxygen homeostasis regulating protein, controlled by PHDs and pVHL-
mediated degradation, is HIF2  (encoded by EPAS1). HIF2  dimerizes also with HIF1
to drive transcription of a distinct set (overlapping partly with HIF1 ) of genes, thus
having somewhat differing effects to HIF1  (Semenza, 2003). The function of the third
HIF  subunit, HIF3 , is less studied. A splice variant of HIF3  encodes an inhibitory
PAS domain protein (IPAS), the expression of which is regulated by HIF1  providing a
negative regulatory feedback for HIF1  (Makino et al., 2007).
As a maintainer of the oxygen homeostasis, HIFs, especially HIF1 , are highly expressed
in many human cancers due to the requirement for oxygenation of an increased number
of cells within a tumor. Moreover, underlying genetic alterations have been observed to
be in association with abnormal expression or degradation of HIF1  (Table 1). For
example, an activating alteration in the AKT pathway can lead to enhanced translation of
HIF1 (Zhong et al., 2000). AKT induces mTOR which regulates the assembly of
translation initiation complexes, and especially translation of growth regulators, such as
HIF1  (Shaw & Cantley, 2006). The transcriptional activity of HIF1 has also been shown
to be regulated through AKT-mTOR pathway. Activated AKT inhibits the function of
TSC1/TSC2 complex enabling positive signal transduction to mTOR/Raptor complex
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which interacts with HIF1 . This interaction enables the binding of HIF1  to its co-
activators CBP and p300 (Land & Tee, 2007).
However, the most marked genetic alteration causing overacive HIF1  (and HIF2 )
signaling is the loss of tumor suppressor VHL in clear cell renal cancers. The disease-
associated mutations in VHL disable its association with HIF1  or with the elongins of
the ubiquitin complex. When the ubiquitylation and degradation of HIF1  in normoxia
is failed, HIF1 and consequently its target genes become abnormally activated (Maxwell
et al., 1999, Zhong et al., 1999, see also 2.2.2.). Evidently, the target genes of HIF1 are
factors that can facilitate tumor growth, for example by neovascularization, metabolic
adaptation, and apoptosis resistance. Furthermore, HIF  overexpression in tumors is
associated with treatment failure and increased mortality in many (but not all) cancer
types (Semenza, 2003). However, it is not yet established whether HIF1 activation is
involved in the actual transformation process.
Table 1. Examples of increased HIF1  due to genetic alterations (modified from Semenza, 2003)
Alteration Mechanism of HIF1  induction Reference
pVHL loss of function  Decreased degradation Maxwell et al., 1999
p53 loss of function
Decreased degradation
Decreased inhibition of HIF1
transcriptional activity
Ravi et al., 2000, Blagosklonny et al., 1998
FH loss of function Decreased degradation Isaacs et al., 2005, Pollard et al., 2005b
SDHB/C/D loss of
function





Zhong et al., 2000, Zundel et al., 2000, Laughner et
al., 2001, Fukuda et al., 2002, Land & Tee, 2007
MEK-ERK (MAPK)
signaling** Increased synthesis Liu et al., 2002, Fukuda et al., 2002 & 2003
SRC gain of function Increased synthesis Jiang et al., 1997
ARF loss of function Decreased inhibition of HIF1
transcriptional activity
Fatyol & Szalay, 2001
ING4 loss of function Decreased inhibition of HIF1transcriptional activity Ozer et al., 2005
CITED4 aberrant
cellular distribution
Decreased inhibition of HIF1
transcriptional activity
Fox  et al., 2004
BCL2 overexpression Decreased degradation (?) Iervolino et al., 2002
*Can be activated for example due to the PTEN loss of function, EGFR signaling (e.g. ERBB2 gain of




The breakdown of genetic integrity seems to be a substantial component in
tumorigenesis as it advances the capability of cancer cells to acquire useful (e.g. growth-
promoting or antiapoptotic) characteristics. These advances may be obtained for
example by down-regulating cellular repair mechanisms. Especially typical for many
cancer tumors is an abnormal karyotype which is defined with changes in chromosome
structure and number. This type of chromosomal instability (CIN) is associated with
telomerase and mitotic checkpoint maintenance, though its origin is not completely
understood. Moreover, in a central role in preventing chromosomal aberrations are
proteins operating in the repair of double-strand DNA breaks occurring in the DNA
replication. These repair mechanisms include homologous recombination (HR) and non-
homologous end joining (NHEJ). (Jefford & Irminger-Finger, 2006) For example, cells
deficient for BRCA1 and BRCA2, which operate in the S-phase checkpoint signaling of
cell cycle, display chromosomal instability due to defective HR (Heinen et al., 2002, Chen
et al., 2008). Thus, a defective double-strand DNA break repair may explain the
increased risk of breast and ovarian cancer in patients with mutated germline alleles of
BRCA1 and BRCA2 (Heinen et al., 2002).
One of the most commonly known cancer-associated genetic instability pathway is
MMR. The primary function of MMR is to eliminate single-base mismatches and
insertion-deletion loops occurring during replication. The human MMR system
comprises proteins taking care of mismatch recognition, including MSH2 which
dimerizes with MSH6 or MSH3 depending on the type of error. A heterodimer of MLH1
and PMS2 coordinates the mismatch recognition complex and the other proteins
involved in DNA strand discrimination, excision, and resynthesis (Buermyer et al., 1999,
Peltomäki, 2003). Inactivating germline mutations in MLH1, MSH2, MSH6, or PMS2
underlie HEREDITARY NON-POLYPOSIS COLORECTAL CANCER (HNPCC) (Liu et al., 1996,
Nyström-Lahti et al., 1996, Wijnen et al., 1999). Moreover, many sporadic tumors of the
HNPCC spectrum (colorectum, endometrium) as well as some other sporadic tumors
have been shown to harbor an MMR gene mutation or promoter hypermethylation
(Peltomäki, 2003). The consequence of defective MMR is a genome-wide microsatellite
instability (MSI) which refers to mismatch errors that occur easily in repeat sequences,
such as microsatellites, although also take place in the coding regions of genes (Jefford &
Irminger-Finger, 2006). The defective MMR system is likely to contribute to
tumorigenesis by failing to repair errors in cancer genes. Recently, tumorigenesis due to
dysfunctional MMR has been shown to be associated with defective apoptosis pathways
as well (Chao & Lipkin, 2006).
NER and BER are repair mechanisms, which are responsible for detecting and
eliminating nucleotides with an altered chemical structure generated for example by a
mutagenic agent. For example, inherited mutations in certain genes operating in NER
cause XERODERMA PIGMENTOSUM (XP) characterized by a decreased ability to repair DNA
mutations caused by ultraviolet exposure, such as sun light. Therefore, the XP patients
are susceptible to melanoma and other skin cancers (Norgauer et al., 2003).
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As these data indicate, tumorigenesis related to the inactivation of proteins operating in
the repair processes are somewhat different from the other cancer-associated pathways
since repression of the genes taking care of the DNA stability results in a higher
mutation rate in other genes also. However, it is notable that genetic material can be
altered with no essential implication on tumorigenesis. Especially MMR-deficient tumors
may harbor a large number of so-called passenger mutations which have no effect on
tumor growth (Futreal et al., 2004).
2.1.2.4. Link between hypoxia and genetic instability
Recently, some of the repair genes were also linked to the hypoxia/HIF1  pathway. It
has long been known that the hypoxic microenvironment is associated with DNA base
substitutions, deletions, and amplifications (Rice et al., 1986, Reynolds et al., 1996, Li et
al., 2001). Moreover, hypoxia is associated with tumor progression and resistance to
therapies (Brizel et al., 1996, Hockel et al., 1996). Theories on the underlying cause of the
hypoxia induced genetic instability include the possibility that the cells under hypoxia
are more exposed to DNA damage or that the repair systems are hindered (Mihaylova et
al., 2003). The latter theory has been justified with the proposal that in hypoxia, only the
mechanisms essential for that condition, such as glycolysis, are supported, but, for
example, cell proliferation and DNA repair would be down-regulated (Koshiji et al.,
2005).
Lately, several studies aiming to determine the pathways related to the hypoxia-induced
instability have been assessed. Evidence for and against the suppression of NER in
hypoxia has been presented, thus its implication in hypoxia-associated instability
remains to be clarified (Yuan, 2000, Bindra et al., 2004 & 2005a). The role of double-
strand break repair has also been a matter of discussion (Huang et al., 2006). Currently it
seems that genes operating in homologous recombination (HR), including RAD51 and
BRCA1, are down-regulated in hypoxia and functional evidence on a reduced capacity to
perform HR has also been given (Bindra et al., 2004, 2005a & 2005b, Meng et al., 2005,
Huang et al., 2006).
At present there is compatible evidence from studies on hypoxia treated cell lines
showing defects in the MMR genes MLH1 and MSH2 (Mihaylova et al., 2003, Koshiji et
al., 2005, Bindra & Glazer, 2007a). As a functional consequence of defective MMR in
hypoxic cells has been observed mutations in a reporter construct as well as MSI in an
endogenous microsatellite locus (Mihaylova et al., 2003, Koshiji et al., 2005). In one
study, in addition to hypoxia, hypoglycemia resulted in the repression of MSH2, which
was suggested to lead to an increased mutation rate of the oncogene k-RAS (Shahrzad et
al., 2005). However, the mechanism by which MMR is repressed in hypoxia has been
under debate. Koshiji and co-workers have suggested the hypoxic effect is mediated by
HIF1 , which displaces the transcriptional activator c-MYC from the MMR gene (MSH2)
promoter (Koshiji et al., 2005). In contrast, Mihaylova and co-workers, and Bindra and
Glazer have shown down-regulation of MMR also in HIF1 -deficient cells, suggesting a
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HIF1 -independent mechanism (Mihaylova et al., 2003, Bindra & Glazer, 2007a). The
hypoxia-induced, HIF1 -independent regulatory system was based on the replacement
of the activating c-MYC-MAX on the MLH1/MSH2 promoter by the repressive MAD1-
MAX and MNT-MAX complexes (Bindra & Glazer, 2007a). Moreover, although the HR
gene BRCA1 expression was originally reported to be regulated by HIF1  (Koshiji et al.,
2004), recent evidence supports BRCA1 and RAD51 rather to be regulated by the
repressive E2F transcription factor (Meng et al., 2005, Bindra et al., 2005a, Bindra &
Glazer, 2007b).
2.1.3. MicroRNAs
The importance of small RNA molecules in cancer formation only started to emerge a
few years ago. MicroRNAs (miRNAs) are a large class of short non-coding RNAs that are
present in plants, animals, and DNA viruses. miRNAs are transcribed from genes as long
primary transcripts that are processed enzymatically to a single-stranded RNA of ~22
nucleotides in length. At present, approximately 500 human miRNA genes have been
identified. The function of miRNAs is not fully understood but they have a role in
growth, development, homeostasis, and disease. miRNAs have been shown to regulate
also several cancer-associated genes controlling cell cycle, apoptosis, cell migration and
angiogenesis. The mechanism by which miRNAs negatively regulate gene expression is
suggested to result from the pairing of miRNA to its target sequence, which in turn
causes the mRNA degradation or inhibition of translation of the target gene (Blenkiron &
Miska, 2007).
The first evidence of a link between miRNA and human cancer came from the
observation that two miRNA genes, mir-15 and mir-16, located on the chromosomal
region that was commonly deleted in chronic lymphocytic leukemia (CLL). Moreover,
expression of these miRNAs was often reduced in CLL (Calin et al., 2002). Subsequently,
several other cancer-associated miRNAs have been identified, also by utilizing miRNA
microarray systems (Lu et al., 2005). It is now emerging that a certain common set of
miRNAs is deregulated in many different tumor types. Since both TSGs and oncogenes
have been shown to be targets of miRNAs, miRNAs can have oncogenic or TSG
properties. Known targets of miRNA regulation include tumor suppressors RB and
TGF -R2, and oncogenes BCL2 and RAS. mir-17-92 polycistron, named as “OncomiR-1”,
is one miRNA with a highly established oncogenic potential (Blenkiron & Miska, 2007).
Interestingly, some miRNAs, such as miR-21, seem to act as a TSG or oncogene
depending on the cell type (Meng et al., 2006, Si et al., 2007). The type of control by
which miRNAs are regulated is not completely understood. The transcription of
OncomiR-1 seems to be directly regulated by the oncogene c-MYC, but with other
miRNAs, regulation by histone acetylation and DNA methylation as well as post-
transcriptional mechanisms has been proposed (Pasquinelli et al., 2000, Calin & Croce,
2006, O’Donnel et al., 2005, Saito et al., 2006). Recently, p53 was shown to control the
expression of specific miRNAs (Raver-Shapira & Oren, 2007). As a potential therapeutics
method against the oncogenic miRNAs has been tested cell-permeable 2-O-methyl
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oligoribonucleotides, “antagomirs” which have already given promising results in
mouse studies (Krützfeldt et al., 2005).
2.1.4. Cancer stem cells
In a multicellular organism, embryonic development is based on the structured division,
differentiation, placing, and elimination of stem cells. Stem cells have also a role in adult
tissues in the maintenance of cell homeostasis during the continuous turnover of cells
and in the case of injury (Bapat, 2007). A normal stem cell is characterized by its self-
renewal capacity that is maintained by symmetric and asymmetric cell divisions. In
symmetric cell division both daughter cells retain the same phenotype and in
asymmetric division a stem and a more differentiated daughter cell are produced. Stem
cells are typically multipotent, i.e. capable of differentiating into different cell
phenotypes (Morrison & Kimble, 2006).
Most tumors are comprised of a heterogenous population of cancer cells which is seen,
for example, as variability in the stages of differentiation and tumorigenic (clonogenic)
potential in in vivo and in vitro assays. The differences between cells within a tumor can
in part be explained by environmental differences as well as by continuing mutagenesis.
However, observations on this variability in the characteristcs of neoplastic cells within a
tumor led a few years ago to the hypothesis that tumors could bear a small, specific
population of cancer cells with similar capabilities to stem cells. These cancer stem cells
(CSC) were hypothesized to possibly represent the tumorigenic population and to be
responsible for the actual tumor cell mass expansion (Reya et al., 2001). The idea of CSCs
has been subsequently supported by the fact that many pathways involved in the
maintenance of normal stem cells are often altered in cancer, including Wnt, -catenin,
PTEN, TGF- , Hedgehog, Notch and Bmi-1 regulated pathways. Moreover, stem cells
with ability to unlimited cell divisions could be considered as prone targets for
transforming events (Polyak & Hahn, 2005).
The present definition of a CSC as proposed by the American Association of Cancer
Research (AACR) workshop on cancer stem cells (2006) is “a small subset of cancer cells
within a cancer that constitute a reservoir of self-sustaining cells with the exclusive
ability to self-renew and to cause heterogenous lineages of cancer cells that comprise a
tumor” (Clarke et al., 2006). However, the central dilemma yet to be untangled is how
the combination of stemness and tumorigenic potential is acquired. The tumors may
derive from stem cells with self-renewal properties which subsequently acquire
epigenetic and genetic changes essential for tumorigenity, or alternatively, the tumor
stem cells could be proliferative progenitors that acquire the self-renewal capacity
(Clarke et al., 2006). The term stem cell has also been considered misleading as the
quantity of the stemness is somewhat questionable (Hill & Perris, 2007). Recently, also
the names tumor-initiating cell and cancer-initiating cell have been used to describe
CSCs (Phillips et al., 2006a, Neuzil et al., 2007). Importantly, the identification of CSCs
has led to the possibility to rethink the way of treating tumors. As conventional therapies
concentrate on targeting the rapidly dividing cells, the stem cells putatively refractory to
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those approaches will probably require completely different methods (Clarke et al.,
2006). However, if the CSCs are the only population with a tumorigenic potential within
a tumor, the elimination of only them would lead to tumor degeneration and the
restriction of disease recurrence (Reya et al., 2001).
2.2. Hereditary renal cancer
Cancer of the kidney accounts for two percent of total human cancers. Approximately
90% of all malignancies of the kidney are renal cell carcinomas (RCC), tumors arising
from the epithelium of the renal tubules. Overall RCC is the twelfth most common
cancer in men and seventeenth most common in women. Smoking and obesity are the
major lifestyle contributors to kidney cancer formation. According to the morphological
features of the tumors, RCCs can be classified into subtypes including conventional
(clear cell), papillary (type 1 and 2), chromophobe, and collecting duct carcinoma. In
addition, benign tumors such as oncocytoma arise from the renal epithelium (WHO
Classification of Tumors 2004; Tumours of the Urinary System and Male Genital Organs,
Cohen & McGovern, 2005). The staging of renal cancers is based on the TNM system (I-
IV) which includes evaluation of tumor size and site, spread to regional lymph nodes,
and metastasis to other organs. This staging, as well as the four-tiered Fuhrman
classification based on the size and regularity of the nuclei and prominence of the
nucleoli, are utilized in the prognosis of the disease. A quarter of the RCC patients
present a locally invasive or metastatic disease, and the aggressive growth is associated
especially with the clear cell and collecting duct tumors (Reuter, 2006). As in the case of
many other tumors, increased risk of renal neoplasia can be inherited. A clear hereditary
predisposition to kidney tumors, RCC or other renal lesions underlies less than four
percent of the cases. As typical for genetic predisposition, the inherited renal neoplasms
are often multifocal and bilateral, and are diagnosed at an earlier age than in general
(WHO Classification of Tumors 2004; Tumours of the Urinary System and Male Genital
Organs). The genesis of sporadic kidney cancer seems not to be affected by hereditable
factors (Lichtenstein et al., 2000).
2.2.1. Hereditary leiomyomatosis and renal cell cancer (HLRCC)
2.2.1.1. Clinical features of HLRCC
HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER (HLRCC, OMIM 605839) is a
dominantly inherited tumor predisposition syndrome which was originally discovered
by a clinical geneticist through the distinct phenotype clustering in one Finnish family.
The clinical manifestations in the family included cutaneous (CLM) and uterine
leiomyomas (ULM), renal cell cancer (RCC), and uterine leiomyosarcoma (ULMS)
(Launonen et al., 2001). Later on, heterozygous germline mutations in the fumarate
hydratase (FH) gene (located on chromosome 1q43) were found to underlie this syndrome
(Tomlinson et al., 2002). To date, more than 130 HLRCC families have been identified
throughout the world. Mostly the families are from North America, the UK, and Finland
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but a few families have been detected outside North America and Europe, for example in
Tunisia and Australia (Tomlinson et al., 2002, Kiuru et al., 2002, Alam et al, 2003, Toro et
al., 2003, Martinez-Mir et al., 2003, Alam et al., 2005a, Chan et al., 2005, Chuang et al.,
2005, Kim, 2005, Varol et al., 2006, Badeloe et al., 2006, Chuang et al., 2006, Wei et al.,
2006, Refae et al., 2007). The population prevalence of allelic variants of FH is not known
(Alam et al., 2005a).
Leiomyomatosis is the most prominent phenotype of HLRCC, and CLMs and ULMs are
seen in all of the HLRCC families. Related to the reduced penetrance of the malignant
tumor types in association with the FH germline mutations, the initial designation for the
syndrome, MULTIPLE CUTANEOUS AND UTERINE LEIOMYOMATOSIS (MCL, OMIM 150800),
is sometimes used alongside HLRCC. Leiomyomas are benign smooth muscle tumors.
The cutaneous tumors are thought to originate from the pilo arrector muscles of the hair
follicle (Alam et al., 2005b). The number and size of the skin lesions in HLRCC patients
vary from a single minor tumor to hundreds of lesions which may be many centimeters
in diameter. The lesions can be painful and sensitive to temperature changes and
pressure. The penetrance of the skin leiomyomas in HLRCC is very high. In a study by
Alam and co-workers, all the male carriers were affected with CLM by the age of 35, and
76% of the female carriers by the age of 45 years (Alam et al., 2005b). Thus, existence of
multiple CLMs is suggested to be a strong indicator of an underlying FH mutation.
ULMs (fibroids) can develop anywhere in the myometrium. Most commonly they locate
within the myometrial wall (intramural ULM), but also close to the endometrium
(submucosal) or serosa (subserosal). Occasionally they can be found in the cervix, broad
ligament, and ovary. In general, hormonal factors and ethnic background influence the
formation of these tumors (Robboy et al., 2000). Approximately 80% of female FH
mutation carriers are affected by ULMs by the age of 45 (Alam et al., 2005b). According
to serial hysterectomy specimens, up to 77% of females in the general population seem
also to be affected by ULMs but clinically they are apparent only in approximately 25%
of females because the tumors can be asymptomatic (Cramer & Patel, 1990). However,
when causing symptoms, i.e. menorrhagia, pain, and reproductive problems, ULMs can
be a significant health issue. In contrast to the cases in the general population, association
of gynecological symptoms in HLRCC patients has been reported in up to 90% of the
cases. Moreover, hysterectomy on FH mutation carriers is commonly performed already
before the age of 30 years, whereas in the general population hysterectomies consequent
on ULMs are usually conducted on females who are over 40 years of age. The early onset
and severity of the clinical symptoms have also effect on family planning decisions (Toro
et al., 2003, Alam et al., 2005b, Hodge & Morton, 2007).
ULMS is the malignant counterpart of ULM and comprises 1% of all uterine
malignancies. ULMSs localized to the uterus cause similar symptoms as ULMs, though
rapid increase in size of the uterus may be indicative for ULMS (WHO Classification of
Tumors 2003; Tumors of the Breast and Female Genital Organs). ULMSs usually arise de
novo and only rarely appear to form from pre-existing ULM (Hart, 2002). These tumors
are highly malignant and in most cases they recur within two years from the primary
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diagnosis and tumor removal (WHO Classification of Tumors 2003; Tumors of the Breast
and Female Genital Organs). Altogether six cases of exceptionally early-onset ULMS
have been reported to date in the context of FH mutation, all of which in the Finnish
population (Launonen et al., 2001, Kiuru et al., 2005, Ylisaukko-oja et al., 2007a). Some of
the other features of ULMS and challenges in the differential diagnosis between ULM
and ULMS will be discussed in section 6.2.2.
The RCCs associated with HLRCC mainly display features of papillary type 2 histology,
large cells with abundant eosinophilic cytoplasm, large nuclei, and prominent inclusion-
like eosinophilic nucleoli. Moreover, the tumors are typically solid, unilateral, and very
aggressive already as small lesions (Merino et al., 2007). Altogether, approximately a
fifth of HLRCC families have cases of RCC, most of which, however, are in Finland and
North America. The prevalence of HLRCC-associated RCC is generally speaking very
low as to date only 56 cases have been reported world-wide (Launonen et al., 2001,
Tomlinson et al., 2002, Alam et al, 2003, Toro et al., 2003, Alam et al., 2005b, Kiuru et al.,
2005, Chan et al., 2005, Badeloe et al., 2006, Chuang et al., 2005 & 2006, Wei et al., 2006,
Refae et al., 2007). As common in hereditary tumor predisposition, the age of RCC onset
in HLRCC is younger than on average with the median diagnosis age of 44 years
(Pithupakorn & Toro, 2006; http://www.geneclinics.org). The youngest RCC case that has
been reported in HLRCC was 16 years of age (Alam et al., 2005b).
2.2.1.2. Fumarate hydratase (FH)
Mitochondria are cell organelles formed of matrix and inner and outer membrane. These
organelles have a central role in energy (adenosine triphosphate, ATP) production since
the oxygen-dependent tricarboxylic acid cycle (TCA cycle) takes place in the
mitochondrial matrix. In addition, mitochondria are involved in a range of other
processes, such as cell signaling, cellular differentiation, apoptosis, and control of the cell
cycle and cell growth (McBride et al., 2006). A mitochondrion has its own genome in a
circular DNA, but many mitochondrial proteins are encoded by nuclear genes
(Anderson et al., 1981).
FH, the predisposing gene of HLRCC, encodes an enzyme of the mitochondrial TCA
cycle (see also 2.4.). The human FH gene is located on the chromosomal region 1q43, and
it generates a transcript of 1.5 kb. FH consists of 10 exons of which the first encodes a
localization signal that targets FH to mitochondria (Tolley & Graig, 1975, Edwards &
Hopkinson, 1979a & 1979b, Kinsella & Doonan, 1986). At least in the case of yeast
fumarate hydratase (Fum1), it seems that the protein import to mitochondria is not post-
translational but exceptionally the translocation and translation of the protein is
physically connected (Karniely et al., 2006, Yogev et al., 2007). The active form of FH is a
tetramer and is comprised of four identical subunits. FH is also found in the cytosol,
where it takes part in the urea cycle. The mitochondrial and cytosolic forms are encoded
by the same gene but the mechanism for the dual distribution of human FH has not been
defined. In the yeast a part of the protein is translocated back to the cytosol from the
mitochondrial outer membrane after the removal of the mitochondrial localization signal
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(Stein et al., 1994, Sass et al., 2001 & 2003). One suggestion related to the retrograde
movement involves the rapid folding of Fum1 into an import-incompetent stage, which
compels the processed protein back to the cytosol (Sass et al., 2003). On the other hand,
the retrograde movement of both the human and yeast fumarase might result from the
poor mitochondrial targeting sequence (Singh & Gupta, 2006).
The mutation spectrum of FH includes 89 different FH mutations identified to date. Of
these changes, the majority are missense (>50%) or nonsense (~10%) mutations, and
frameshift (~20%) mutations caused by either small insertions or deletions. A few splice
site mutations and inframe deletions or insertions of one to two amino acids, one exon 7
duplication, and two whole gene deletions have also been found. The mutations lie
throughout the gene, an exception being exon 1 (Tomlinson et al., 2002, Kiuru et al., 2002,
Alam et al, 2003, Toro et al., 2003, Martinez-Mir et al., 2003, Alam et al., 2005c, Chan et
al., 2005, Chuang et al., 2005, Kim, 2005, Varol et al., 2006, Badeloe et al., 2006, Chuang et
al., 2006, Wei et al., 2006, Refae et al., 2007, Campione et al., 2007, Ylisaukko-oja, 2007).
Since the malignant tumors of HLRCC have been observed only in certain populations
and families, attempts have been made to determine the influence of the mutation type
and site to the phenotype, yet no clear correlation has been found. FH is considered to be
a TSG as the majority of the associated tumors are found with biallelic inactivation of FH.
Mostly the tumors display loss of the wild-type allele, but point mutations as second hits
have also been observed (Launonen et al., 2001, Kiuru et al., 2002).
FH DEFICIENCY (FHD, MIM 606812), is an autosomal recessive condition caused by
homozygous (or compound heterozygous) germline mutations in the FH gene and was
originally described in 1986 by Zinn and co-workers (Zinn et al., 1986). The clinical
outcome of the patients includes psychomotor retardation, muscular hypotonia,
microcephaly, and occasionally also seizures and dysmorphic facial fetures (Kerrigan et
al., 2000, Deschauer et al., 2006). Fumarate excretion in the urine is one clear indicator of
FHD. Patients of FHD usually die at a few months of age but some survive nearly their
first decade (Bourgeron et al., 1994). FH enzyme activity in the heterozygous parents’
tissues is around 50% and in the patients’ very low, varying from 0.2% to 23% compared
to control samples (Zinn et al., 1986, Petrova-Benedict et al., 1987, Gellera et al., 1990,
Remes et al., 1992, Bourgeron et al., 1994, Deschauer et al., 2006). Due to the FH defect,
fumarate has been shown to accumulate in cells and inhibit SDH, aspartase,
adenosuccinate lyase, and arginosuccinase. Hence, inhibition of many other enzymatic
pathways in addition to the oxidative phosphorylation has been suggested as having an
important role in the pathophysiology of FHD (Deschauer et al., 2006). Altogether 18
distinct FH mutations have been reported in FHD families (Gellera et al., 1990,
Bourgeron et al., 1994, Rustin et al., 1997, Coughlin et al., 1998, Alam et al., 2003, Remes
et al., 2004, Loeffen et al., 2005, Pollard et al., 2005b, Maradin et al., 2006, Phillips et al.,
2006b, Zeng et al., 2006, Deschauer et al., 2006, Ylisaukko-oja, 2007). Of these 18
mutations six are associated also with HLRCC (tumorigenesis of leiomyomas, RCC or
ovarian cystadenoma). They are located at four different exons and include five point
mutations (R58X, K187R, R190H, R190C and H275Y) and one amino acid insertion
(435insK) (Toro et al., 2003, Wei et al., 2006, Ylisaukko-oja et al., 2006b). The FH
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mutations in FHD are usually of the missense type, and it has been postulated that the
biallelic truncating mutations are likely to be embryonic lethal (Tomlinson et al., 2002,
Alam et al., 2003). Since the mutation spectrum overlaps with FHD and HLRCC, it is
surprising that only a couple of CLM cases have been reported in heterozygous FH
mutation carriers in FHD families (Tomlinson et al., 2002, Maradin et al., 2006).
2.2.2. Other hereditary forms of renal cancer
The most common inherited RCC syndrome is the VON HIPPEL LINDAU disease. The
syndrome is associated with hemangioblastomas of the central nervous system and
retina, RCC, renal cysts, pheochromocytoma (PHEO, see also 2.3), as well as with some
other benign and malignant tumors. RCC is found in 24-45% of VHL cases. Of the four
phenotypic subclasses of VHL (1, 2A, 2B, 2C), RCC is present in type 1, type 2B, and
sometimes in 2A. The tumors display clear cell histology and are often bilateral and
multifocal (Lonser et al., 2003). This autosomal dominant disease is caused by mutations
in the tumor suppressor VHL. VHL is commonly associated with the genesis of sporadic
RCCs as well, since LOH of 3p (location of VHL) has been observed in 95% of sporadic
clear cell tumors. Inactivation of the other allele by mutation or hypermethylation is seen
in over half of the sporadic cases (Gnarra et al., 1994). Since pVHL acts as a negative
regulator of HIF  proteins (HIF1  and HIF2 ), inactive pVHL allows abnormal
activation of the HIF pathways (Seitzinger et al., 1988, Latif et al., 1993, Maxwell et al.,
1999, see also 2.1.2.2.). Of note, HIF activation takes place already in the early lesions
(dysplastic and cystic lesions) in the VHL patients’ kidneys so that HIF1  accumulation
is switched to HIF2  accumulation when the degree of dysplasia increases. This would
suggest that HIF2  has a more oncogenic role in the setting of VHL-defective RCC. The
additional genetic changes probably required for the transformation of the preneoplastic
cysts have, however, not yet been determined (Mandriota et al., 2002, Kim & Kaelin,
2006). Since not all types of VHL mutations cause RCC (as in the case of type 2C VHL
with PHEOs only) and lead to activation of HIF, pVHL’s role in other cellular processes
(e.g. extracellular-matrix deposition and turnover, epithelial differentiation), possibly
distinct from HIF mediated effects, may be involved specifically in the formation of
PHEOs (Clifford et al., 2001, Kim & Kaelin, 2003). In addition, pVHL has an important
part in stabilizing p53 in response to genotoxic stress (Roe et al., 2006).
HEREDITARY PAPILLARY RENAL CARCINOMA (HPRC) is dominantly inherited disorder
characterized by RCCs of type 1 papillary growth pattern, small cells, low Fuhrman
grade (1-2), and inconspicuous cytoplasm and nucleoli (Zbar et al., 1994, Lubensky et al.,
1999). The tumors are bilateral and multiple, and even up to 3000 microscopic tumors
have been found from an affected kidney (Ornstein et al., 2000). The predisposition is
transmitted by germline mutations in the c-MET oncogene located on chromosome 7q
(Schmidt et al., 1997). c-MET is a tyrosine kinase and it is located on the cell surface as a
receptor for the hepatocyte growth factor (HGF). Activation of c-MET by its ligand HGF
or through a mutation results in the initiation of multiple signal transduction cascades
involved in proliferation, migration, and morphogenesis (see also 2.1.2.1.). HPRC
tumorigenesis appears to involve the gain of function of the mutant c-MET as the tumors
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from HPRC patients and from the mutant c-Met mouse model harbor the duplication of
the chromosome containing the mutant allele (Zhuang et al., 1998, Graveel et al., 2005).
In sporadic papillary tumors, c-MET mutations are observed quite rarely, indicating
differential molecular pathways in the genesis of hereditary and sporadic papillary RCC
(Schmidt et al., 1999).
TUBEROUS SCLEROSIS (TS) is characterized by multiple hamartomas in several organs.
Those in the central nervous system may result in a learning disability, seizures, and
behavioral problems. Associated renal lesions include angiomyolipomas, renal and
perirenal cysts, RCCs, and oncocytomas (Lendway & Marshall, 2003). The two
predisposing genes of this dominantly inherited syndrome, TSC1 (on 9q) and TSC2 (on
16p), encode peptides for a protein dimer acting as a negative regulator of the cancer-
associated PI3K-AKT-mTOR pathway (European Chromosome 16 TS Consortium 1993,
van Slegtenghorst et al., 1997, Hay, 2005, Astrinidis & Henske, 2005, see also 2.1.2.1.).
Interestingly, the first ever naturally occurring hereditary cancer in an animal model was
the “Eker rat” (Eker et al, 1981), which was later on identified with a germline mutation
in Tsc2 (Hino et al., 1994, Yeung et al., 1994). The phenotype of the rat includes RCC,
hemangiomas/hemangiosarcomas of the spleen, ULM/ULMS, and pituitary adenomas
(Hino et al., 2003).
BIRT-HOGG-DUBE (BHD) syndrome is an autosomal dominant disease, initially
characterized by different types of cutaneous lesions (Birt et al., 1977). Predisposition to
RCC was later connected to BHD (Roth et al., 1993, Toro et al., 1999). The features of the
renal tumors in BHD are variable. The tumors are mainly oncocytomas, but
chromophobe, and clear cell type tumors are found as well (Pavlovich et al., 2002). The
predisposing gene (BHD) is located on 17p and encodes folliculin protein (Nickerson et
al., 2002). The actual function of the protein is not known but it is suggested to operate as
TSG (Vocke et al., 2005).
COWDEN SYNDROME (CS) is an autosomal dominant disorder characterized by multiple
hamartomas, commonly as mucocutaneous manifestations. Moreover, benign and
malignant tumors of the breast, thyroid, and endometrium are commonly observed. As
well as several other types of lesions, the patients are occasionally observed with RCC or
ULMs. The predisposition to CS is caused by mutations in the tumor suppressor PTEN,
encoding a lipid and protein phosphatase affecting on cell growth, spread, and
apoptosis. These functions are mediated by its regulatory role in the PI3K-AKT and
MAPK pathways as well as in focal adhesion (Gustafson et al., 2007). Recently, PTEN has
been suggested to regulate certain double-strand DNA break repair proteins and thus
have also a role in maintaining chromosomal integrity (Shen et al., 2007). Gene and
protein loss of PTEN have also been observed in sporadic RCCs as well as in many other
sporadic cancers (Brenner et al., 2002, Velickovic et al., 2002, Shen et al., 2007).
HYPERPARATHYROIDISM-JAW (HPT-JT) patients typically manifest ossifying fibroma of the
jaw, parathyroid adenomas, benign cysts and hamartomas of the kidney, Wilms’ tumor,
and papillary RCC (Szabo et al., 1995). Heterozygous germline mutations in the
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predisposing gene HPRT2 (on 1q) are found in over half of HPT-JT patients, and genetic
evidence indicates it acts as TSG (Carpten et al., 2002). HPRT2 is mutated also in a
fraction of sporadic parathyroid and renal tumors. The gene product of HPRT2 is
parafibromin, a component of the RNA polymerase II associated factor. The function of
parafibromin is still unclear but at least certain mutations result in the defective
suppression of cyclinD1 and consequent abnormal cell proliferation (Zhao et al., 2007).
Other familial inheritance of RCC includes families with a TRANSLOCATION OF 3p (Bonne
et al., 2004), and HNPCC. HNPCC-associated uroepithelial cancers results from
inactivation of the MMR genes, of which MSH2 seems to be mostly associated with
extra-colonic tumors (Vasen, 2005, see also 2.1.2.3.). An underlying SDHB mutation has
been observed in three RCC cases (two solid, and one clear cell) in the context of
HEREDITARY PARAGANGLIOMATOSIS (Vanharanta et al., 2004, see also 2.3.) BECKWITH-
WIEDEMANN SYNDROME (BWS), of which susceptibility gene is located on 11p15.5, is an
overgrowth syndrome occasionally associated with Wilms’ tumor (Smith et al., 2007).
These hereditary RCC-associated syndromes are summarized in Table 2. In addition,
there is a group of familial non-syndromic clear cell carcinomas which is not linked to
any of the above-mentioned syndromes (Woodward, 2004).
2.3. Hereditary pheochromocytoma and paraganglioma
Paraganglia are aggregations of cells originated from the embryological neural crest and
located throughout the body in the vascular and neuronal adventitia. The tumors arising
from these neuronal cells include paragangliomas (PGL) and pheochromocytomas
(PHEO). When the tumor is originated from the symphatetic nervous system and it
secretes catecholamines, the tumor is referred to as PHEO. These tumors are most
commonly located in the adrenal medulla (a modified ganglia), but also extra-adrenal
PHEOs exist (also called symphatetic PGLs). Head and neck PGLs are derived from the
parasymphatetic ganglia, and they commonly arise from the carotid body (an oxygen
sensing organ). PGLs, like normal paraganglia, comprise type II (sustentacular) and type
I (chief) cells, of which the latter ones represent the neoplastic population. The
nomenclature of these lesions is somewhat confusing and often tumors of head and neck
are named PGLs while tumors below neck are termed PHEOs (van Schlothorst et al.,
1998, Maher & Eng, 2002, Jiménez et al., 2006, Martin et al., 2007).
PGLs/PHEOs are rare, estimated to comprise 0.01% of human tumors (Martin et al.,
2007). These neoplasms are mainly benign but a malignant potential (defined by
metastasis) is seen in 6-19% of PGLs/PHEOs of different sites (Myssiorek, 2001). A
familial clustering of PGLs was observed for the first time in 1964 in two siblings (Kroll
et al., 1964). The mapping of the predisposing gene for HEREDITARY
PARAGANGLIOMATOSIS (HPGL) started in the Netherlands, which led to the identification
of locus on 11q23, named PGL1.  Later  the  locus  was  found  to  contain  the  gene  of
succinate dehydrogenase subunit D (SDHD), and germline mutations in the gene to explain
head and neck PGLs in a subset of the studied PGL families (Baysal et al., 2000). Families
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harboring a germline SDHD mutation were observed to display a phenotype with PGLs
only or combined with PHEOs. Moreover, families with PHEOs only were found (Maher
& Eng, 2002) (Table 2). The PGL/PHEO phenotype, caused by an SDHD mutation, is
shown only in paternal transmission, suggesting maternal imprinting of the gene (van
der Mey et al., 1989, Baysal et al., 2000). However, according to biallelic expression of
SDHD in certain tissues and the consistent loss of the wild-type (maternal) allele in the
associated tumors, it seems that the maternal allele is actually expressed in the normal
paraganglia. Indeed, recent studies have shown that SDHD PGLs display an entire loss
of maternal chromosome 11. The tumorigenesis is now suggested to involve the loss of
the wild-type SDHD allele as well as the loss of an unknown paternally imprinted gene
located on chromosome 11p. This transmission mode would explain the only paternally
expressed phenotype (Hensen et al., 2004).
SDHD is part of the SDH enzyme, comprised of four subunits SDHA/B/C/D, which
operates in the TCA cycle as well as in the respiratory chain as a part of the
mitochondrial complex II. In the TCA cycle, SDH catalyzes the oxidation of succinate to
fumarate. In addition to SDHD, other subunits of SHD have been linked to hereditary
paragangliomatosis. The PGL3 locus on 1q21 and PLG4 on 1p36 contain genes encoding
SDHC and SDHB, respectively. Association of these genes with familial PGLs (SDHC)
and  both  PGLs  and  PHEOs  (SDHB) has been observed in a few families (Niemann &
Muller, 2000, Astuti et al., 2001). Moreover, a putative PGL2 locus on 11q13 is linked to a
large Dutch PGL family but no susceptibility gene has been identified yet (Mariman et
al., 1995) (Table 2). SDHB and SDHC are TSGs (as SDHD) and display somatic loss of the
wild-type allele in the tumor (Gottlieb & Tomlinson, 2005). Specifically SDHB mutations
have been linked to the malignant outcome of the tumors since 34-71% of the SDHB
carriers are found with a metastatic disease (Gimenez-Roqueplo et al., 2003, Neumann et
al., 2004, Amar et al., 2007). Recently malignant tumors have been observed in SDHD
cases too (Havekes et al., 2007, Timmers et al., 2007). In contrast to the association of
SDHB/C/D with tumorigenesis, homozygous germline mutations in the fourth SDH
subunit, SDHA, result in degenerative disorders such as an infantile
encephalomyelopathy called Leigh syndrome and a disorder with late-onset optic
atrophy, ataxia, and myopathy (Bourgeron et al., 1995, Birch-Machin et al., 2000).
PHEOs are also components of other familial cancer syndromes including VHL, MULTIPLE
ENDOCRINE NEOPLASIA 2 (MEN2), and rarely NEUROFIBROMATOSIS TYPE I (NF1) (Pacak et al.,
2001) (Table 2). In the VHL syndrome, caused by mutations in the tumor suppressor
VHL, PHEOs are associated with type 2 (2A, 2B, 2C) disease comprising 10-15% of the
VHL cases. (Maher & Eng, 2002, Lonser et al., 2003, see also 2.2.2.). A mutation in the
oncogene RET underlies 95% of MEN2A and MEN2B cases, the clinical subtypes of
MEN2 (Eng et al., 1996). PHEOs are present in approximately half of MEN2 patients.
Another endocrine tumor type observed in MEN2B is medullary thyroid carcinoma and
MEN2A patients are additionally affected by parathyroid hyperplasia (Maher & Eng,
2002). NF1, associated with germline mutations in NF1 (neurofibromin 1), is classically
characterized by “café au lait” spots, cutaneous neurofibroma, and tumors of the
nervous system (Kramer et al., 2007).
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Table 2. Hereditary  tumor  syndromes  associated  with  renal  lesions,  paragangliomas,  and
pheochromocytomas
RCC: renal cell carcinoma; PGL, paraganglioma; PHEO, pheochromocytoma; TSG, tumor suppressor gene
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In the analyses of apparently sporadic PHEOs, an underlying germline mutation
predisposing to PGL/PHEO (SDH, VHL, RET) is found in 10-24% of cases (Neumann et
al., 2002, Gottlieb & Tomlinson, 2005, Jimenez et al., 2006, Martin et al., 2007). The role of
intragenic somatic mutations in these genes in genesis of true sporadic tumors is,
however, minor (Eng et al., 1995, Hofstra et al., 1996, Gimm et al., 2000).
2.4.  Tricarboxylic acid cycle defect and tumorigenesis
In the presence of oxygen, the aerobic step in the energy production, cellular respiration,
takes place. Pyruvate formed in cytosolic glycolysis, fatty acids, and some amino acids
are oxidized to yield two-carbon fragments in the form of acetyl-coenzyme-A (Acetyl-
CoA). These acetyl groups then enter the tricarboxylic acid cycle (TCA cycle) which
enzymatically oxidizes them to CO2. In brief, the TCA cycle encompasses the following
steps: Acetyl-CoA is condensed by oxaloacetate and citrate synthase to citrate. Aconitase
catalyzes the conversion of citrate to isocitrate, which is oxidized to -ketoglutarate by
isocitrate dehydrogenase (yielding CO2). The -ketoglutarate is dehydrogenated and
decarboxylated to succinyl-CoA (and CO2) by -ketoglutarate dehydrogenase. It reacts
with ADP and Pi to form succinate and ATP (the only one formed straight from the TCA
cycle) which is catalyzed by succinyl-CoA synthase. Succinate is then oxidized to
fumarate by SDH. Fumarate is hydrated by FH to L-malate, which is oxidized by L-
malate dehydrogenase to regenerate oxaloacetate. The energy released from these
oxidation reactions is conserved in the reduced electron carriers NADH and FADH2
(Stryer, 1999, Nelson & Cox, 2000) (Figure 1).
Figure 1. The tricarboxylic acid
cycle. In the first stage of cellular
respiration Acetyl-CoA is formed
e.g. by oxidation of pyruvate
obtained from glycolysis of
glucose.  In  the  second  step,
Acetyl-CoA is oxidated in the
TCA  cycle,  which  yields  CO2, an
ATP, and reduced electron
carriers  NADH  and  FADH2.
NADH and FADH2 proceed into
the third stage, electron transfer
chain in which the flow of
electrons drives the production of
ATP. In this respiration process
altogether 32 ATPs are formed
from one glucose molecule. In
addition  to  energy  (ATP)
production, TCA cycle provides
precursors (such as -
ketoglutarate and oxaloacetate)
                       for  many  biosynthetic  pathways
                     (Nelson & Cox, 2000).
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Subsequently the electron carriers, NADH and FADH2 are themselves oxidized,
releasing protons and electrons. In the next step, in the electron transfer chain on the
mitochondrial inner membrane, the free electrons are transferred to O2. In the course of
the electron transfer, a large amount of energy is produced by the oxidative
phosphorylation of ADP to ATP (Stryer, 1999, Nelson & Cox, 2000).
HLRCC and HPGL are tumor predisposition syndromes caused by mutations in genes
encoding the TCA cycle enzymes FH and SDH (subunits SDHB/C/D). As well as the
TCA cycle, SDH operates in the electron transport chain. It is interesting that defects in
energy production seem to contribute to tumorigenesis rather than cause cell death.
Several hypotheses and also evidence of the relation of the TCA cycle to resistance to
apoptosis, increased redox stress, and activation of HIF1 have been put forward (Gottlieb
& Tomlinson, 2005). The apoptosis-related theories have been based on the central role of
mitochondria in apoptotic processes. Subsequently, the defect in the mitochondrial TCA
cycle has been suggested to generate apoptosis-resistant cells including a theory based
on the up-regulation of glycolytic pathways as a consequence of the down-regulation of
oxidative phosphorylation (Newmeyer & Ferguson-Miller, 2003, Gottlieb & Tomlinson,
2005). Glycolytic enzymes have, among other functions, the capability to block apoptosis
(Kim & Dang, 2005). On the other hand, SDH, SDHC particularly, has been implicated in
cell line studies to potentially act as an apoptosis regulator (Albayrak et al., 2003, Ishii et
al., 2005, Gottlieb & Tomlinson, 2005). Curiously, in these studies the acute response to
the down-regulation of SDH was induction of apoptosis, whereas the chronically SDH-
deprived cells became tumorigenic (Albayrak et al., 2003, Ishii et al., 2005). However, it
remains elusive whether the effects seen in the cell line studies are meaningful in SDH-
deficient tumors. Moreover, mutations in the subunit C are not that common. The
apoptosis response was shown to be triggered by reactive oxygen species (ROS),
generated due to the defective SDH (Albayrak et al., 2003, Ishii et al., 2005). Additionally,
ROS were suggested to increase mutagenesis and thereby drive the tumorigenic progress
(Ishii et al., 2005). However, ROS production has not been observed in all the studies on
SDH- or FH-deficient cells and thus its role HLRCC and HPGL tumorigenesis remains
unclear (Selak et al., 2005, Pollard et al., 2005b).
Evidently, activation of HIF1 is one of the consequences of the TCA cycle defect. The
physiological function of HIF1 is to orchestrate cells’ adaptation and survival in low
oxygen conditions by inducing oxygen-independent glycolysis as an energy source and
also vessel growth. It was first indicated in SDH- and then in FH-deficient tumors that
the defective function of these enzymes leads to accumulation of their substrates,
succinate and fumarate, respectively. These in turn were shown to inhibit PHD (prolyl
hydroxylase-domain) enzymes under normoxic conditions triggering a stage of
“pseudohypoxia”. In pseudohypoxic cells, the normal targeting of HIF1  subunit to
degradation is hindered and activation of HIF1 target genes is enabled (Selak et al., 2005,
Isaacs et al., 2005, Pollard et al., 2005b, see also 2.1.2.2) (Table 1, Figure 2). For example,
FH-deficient ULMs have been shown to express increased levels of HIF1 targets such as
glycolytic enzymes and angiogenic factors (e.g. VEGF) as well as display increased
microvessel density (Pollard et al., 2005a & 2006, Vanharanta et al., 2006, Catherino et al.,
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2007). Also overexpression of HIF2  has been observed in the context of FH and SDH
down-regulation, but to a lesser extent than that of HIF1  (Pollard et al., 2006 & 2007). In
contrast, since fumarate and succinate do not seem to repress FIH1, the inhibitor of the
transcriptional activity of HIF1, FH and SDH mutations are not likely to influence on the
transcription of HIF1 target genes by altering FIH1 function (Koivunen et al., 2007).
The role of the TCA cycle intermediates as inhibitors of PDHs is well established and
fumarate especially has been shown to efficiently prevent the function of all the PHDs
(Koivunen et al., 2007). Moreover, there is a clear association between HIFs and the
features that HLRCC and HPGL tumors display, such as high vascularization, but
whether up-regulation of HIFs is sufficient to cause the actual tumorigenesis is still
under investigation. The PHD catalyzed proline hydroxylation of HIF1 /HIF2  (HIFs)
takes place through a reaction of conversion of molecular oxygen and -ketoglutarate to
CO2 and succinate. Interestingly, -ketoglutarate supplied to cells with excessive
fumarate or succinate has been shown to compete for the PHD interaction and to restore
the normal PHD function. This provides one potential basis for therapeutical aspects
(MacKenzie et al., 2007). However, it is notable that the possible role of inhibition of
dioxygenases other than the PHDs in TCA cycle-associated tumorigenesis has not yet
been evaluated (Koivunen et al., 2007, Pollard et al., 2007).
Figure 2. Activation of the HIF1
pathway due to defective SDH and
FH. Inactivating mutations in SDH
and FH (marked  with  asterisks)
cause accumulation of their
substrates, succinate and fumarate,
respectively. These inhibit similarly
to low oxygen the oxygen-
dependent function HIF1  prolyl
hydroxylase-domain (PHD)
proteins. Non-hydroxylated HIF1
is able to enter the nucleus,
dimerize with HIF1 , and activate
the transcription of factors
facilitating  tumor  growth.  In
contrast, normally hydroxylated
(OH) HIF1  is recognized by the
tumor  suppressor  pVHL,  which
targets it to ubiquitylation (Ub) and
degradation. HIF2  is similarly
activated by pseudo-hypoxia,
although to a lower extent than
HIF1  (Semenza, 2003, Selak et al.,
2005, Isaacs et al., 2005, Pollard et
al., 2005b, Figure modified from
Esteban & Maxwell, 2005).
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Separate from the HIF pathway, inherited mutations in the genes (SDH, VHL, RET, NF1,
see also 2.2.2.) predisposing to PGLs/PHEOs were recently shown to share a common
pathway leading to tumorigenesis. PGLs/PHEOs originate from neural crest cells, which
during embryonic development undergo c-JUN dependent apoptosis when neuronal
growth factor (NGF) becomes limited. Mutant forms of these genes seem to result in
failure of the normal apoptosis. Hence, the survived neural crest cells have been
suggested to have tumorigenic potential and act as neoplastic progenitors for
PGL/PHEO (Lee et al., 2005, Maxwell, 2005).
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3. AIMS OF THE STUDY
1) To elucidate the clinical characteristics of hereditary leiomyomatosis and renal cell
cancer (HLRCC)
 by specifying the risk of cancer, the tumor spectrum and tumor characteristics of
HLRCC
2) To elucidate the molecular characteristics of HLRCC and hereditary
paragangliomatosis (HPGL)
 by studying the putative link between HIF1  and mismatch repair in HLRCC and
HPGL tumors
 by characterizing the novel alternative transcript of FH (FHv)
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4. MATERIALS AND METHODS
4.1. Sample material
4.1.1. Finnish HLRCC families and patients (I-IV)
Finnish hereditary leiomyomatosis and renal cell cancer (HLRCC) families found so far
include seven families that have been identified through a benign (leiomyomatosis) or
malignant (renal cell cancer; RCC or uterine leiomyosarcoma; ULMS) phenotype. In
addition, one FH deficiency (FHD) family has been reported in Finland (Table 3).
In study I, the eight Finnish FH mutation-positive families were extended and
prospected for cancer cases as described in section 4.2. The FH mutation status was
analyzed from all the available individuals, and subsequently all the available tumors
from the FH mutation carriers were studied for biallelic inactivation of FH. Varying sets
of these tumors were then used in the subsequent approaches (studies II, III, IV). In
addition to the tumors identified through the search in study I, uterine leiomyomas
(ULM) as described previously (Launonen et al. 2001, Kiuru et al., 2001, Tomlinson et al.
2001, Kiuru et al., 2002, Vanharanta et al., 2006) were utilized in studies III and IV.
Table 3. Finnish HLRCC families
Family Phenotype exploited in
family identification
Germline mutation* Reference
FAM1 RCC E181fs** Launonen et al., 2001
FAM2 RCC E181fs** Launonen et al., 2001
FAM3 Leiomyomas R300X Tomlinson et al., 2002
FAM4 ULMS H153R Study I
FAM5 RCC H153R Study I
FAM6 ULMS H153R Kiuru et al., 2002
FAM7 Leiomyomas E181fs** Kiuru et al., 2002
FAM8 FHD Q333P Remes et al., 1992 & 2004
RCC; renal cell cancer, ULMS; uterine leiomyosarcoma
*Site of the mutation in the FH sequence is calculated starting from the last codon of exon 1 (encoding the signal
peptide) (Tomlinson et al., 2001). **Corresponding mutation name 541delAG used in the original publications.
The frameshift results in a premature stop codon and truncated protein product.
4.1.2. Spanish HLRCC patient case (II)
A germline FH mutation analysis of the Spanish RCC patient and the patient’s mother
was conducted from blood-extracted DNA. DNA from the patient’s two paraffin-
embedded renal tumors was used for FH and VHL mutation analyses and for 3p LOH
analysis. RCC tissue sections were analyzed for histological and immunohistochemical
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(IHC) characteristics. The patient’s two uterine leiomyomas also were histologically
evaluated. Three RCCs from FAM1 were exploited as controls in the IHC.
4.1.3. Samples exploited in the analysis of HIF1  and mismatch repair (III)
4.1.3.1. HLRCC samples
Paraffin-embedded HLRCC tumors from Finnish FH mutation carriers including 11
RCCs, 12 ULMs, one ULMS, and as a control, four non-familial ULMs were analyzed in
studying the relation between HIF1  and MSH2 protein expression. Microsatellite
instability (MSI) was analyzed from DNA of the respective RCCs (n=10), ULMs (n=8),
and ULMS (n=1) as well as from another four HLRCC-associated ULMs. Corresponding
normal DNA was used as a control when available.
4.1.3.2. HPGL samples
A tissue microarray slide (TMA) containing 17 PHEOs and 100 PGLs was analyzed
similarly as the HLRCC samples. The 117 tumors comprised 63 SDHB/C/D mutation-
positive (62 PGLs and 1 PHEO), 9 other familial (NF, VHL, RET, PGL2) and 45 non-
familial tumors. All the samples in the array were represented as triplicates. Seventeen
PGL tumor DNA samples (9 SDHD,  1 PGL2, and 7 non-familial) corresponding to the
array samples as well as 10 additional samples (9 SDHD and 1 PGL2) were used for MSI
analysis. If available, corresponding normal DNA was used as a control.
4.1.4. Samples exploited in the analysis of the alternative transcript of FH (FHv) (IV)
4.1.4.1. Mutation analysis of FH exon 1b
A total of 139 human DNA samples were screened for FH exon 1b mutations including
21 cell lines (12 RCC, 4 prostate cancer, 5 sarcoma cell lines), 99 non-syndromic HLRCC-
associated tumors (39 ULMs, 43 RCCs, and 17 ULMSs), 9 HLRCC patient-derived
tumors without detected second hits in FH (study I, Vanharanta et al., 2006), and 10
blood samples from FH mutation-negative individuals (6 cases with early-onset RCC,
and 4 cases with RCC or leiomyomatosis).
4.1.4.2. Expression analysis of FH exon 1b
FH exon 1b expression was analyzed in fetal (skeletal muscle, lung, brain, kidney, liver,
heart, spleen, thymus) and adult (skeletal muscle, lung, brain, kidney, liver, heart,
placenta, pancreas) human tissue cDNA (Human MTCTM Panel 1 and Human Fetal
MTCTM Panel, BD Biosciences Clontech, Palo Alto, CA). Moreover, expression of 1b was
analyzed in 15 cell lines (see 4.7.1.).
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4.2. Genealogy and cancer data collection (I)
To broaden the knowledge about the tumor spectrum of HLRCC, particularly about
malignant tumors, an extended search for family and cancer data was performed on the
eight Finnish FH-mutation-positive families (see 4.1.1., Table 3). The genealogical data of
the families were collected through church parish registries and the Population Register
Centre. Population registration in Finland began in the 16th century and in 1967 each
resident in Finland was given a personal identifier (PID) enabling rapid tracking of
family members. Family branches observed to be FH mutation-negative were not further
followed and were therefore not included in the study. Cancer history of the identified
individuals was verified from the Finnish Cancer Registry and death certificates. Cancer
data was subsequently utilized in the collection of tumors for FH mutation analysis and
for calculating the incidence of cancer in HLRCC families compared to the general
population. Existence of other lesions (mainly kidney cysts and adrenal gland tumors)
was examined from patient reports if available. The data collection process is illustrated
in Figure 3.
Figure 3. Process of the genealogy, cancer data, and sample collection of Finnish FH mutation-positive
families. DNA samples for FH germline  mutation  analysis  were  obtained  in  addition  to  blood
extracted lymphocytes also from paraffin embedded tumor tissue.
4.3. Statistical analyses (I)
The cancer risk in FH mutation-positive families compared to the general population
was calculated with the standardized incidence ratio (SIR). The family members were
followed up for cancer incidence by a personal identifier-based (PID) automatic record
linkage with the Finnish Cancer Registry. The follow-up started on January 1st 1953 and
ended on December 31st 2002 or at a person’s death or date of emigration. Individuals
deceased before 1967 with no PID were excluded from the Cancer Registry search. To
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avoid the ascertainment bias inherent in the family identification, the lowest possible
estimate of the cancer risk was calculated. This was done by excluding cancers in all the
index patients (five cancers in eight patients) and the other patients with RCC or ULMS
(seven cancers in six patients) used for the identification of the families. Moreover, to
avoid selection bias, only completely traced generations were included in the analysis.
No selection according to mutation status was made. The total number of family
members included in SIR analyses was 256. The SIRs were calculated by dividing the
observed numbers of cancer cases by expected numbers. The expected numbers were
based on person-years at risk and population-based gender-, age-, and calendar periodic-
specific incidence rates in the general population. Exact 95% confidence intervals (CI)
were defined assuming that numbers of observed cases followed the Poisson
distribution. Comparison of the age at cancer diagnosis between FH mutation carriers
and non-carriers were calculated by Fisher’s exact test.
4.4. Genetic analyses
4.4.1. Mutation analysis (I-IV)
Mutation analyses were performed by direct sequencing. Standard procedures were
used for the extraction of DNA from normal (lymphocyte/tissue) or tumor samples.
Polymerase chain reaction (PCR) with AmpliTaq Gold® DNA polymerase (Applied
Biosystems Foster City, CA, USA) was used for amplification of DNA fragments. Next,
the excess of deoxynucleotides was purified by ExoSAP-IT enzyme mix (USB
Corporation, Cleveland, Ohio, USA) and the fragments were analyzed using BigDye 3.1
chemistry and ABI3730xl DNA Analyzer (Applied Biosystems). In studies I and II, in
order to identify FH mutation carriers and LOH in tumors, FH exons 1-10 were analyzed.
FH primer sequences are described by Kiuru and co-workers (2002). The FH exon 1b
mutation status was analyzed with 1b specific primers (study IV) and VHL with three
exons in order to exclude the contribution of the VHL defect in the tumorigenesis of the
Spanish RCC case (study II). FH 1b and VHL primer sequences are described in Table 4.
Table 4. Sequencing primers of FHv exon 1b and VHL
Purpose Study F sequence 5’-3’ R sequence 5’-3’
FH ex 1b IV GGCTGTCAGAGAGGGTCCTA TACGGGGGAAACCATAGTCA
VHL ex 1 (1st fragment)  II CGCGAAGACTACGGAGGT GGCCTCCATCTCCTCCTC
VHL ex 1 (2nd fragment)  II GAGTACGGCCCTGAAGAAGA CGGTAGAGGGGCTTCAGAC
VHL ex 2 II AGCCAGGACGGTCTTGATCTC GGCAAAAATTGAGAACTGGGC
VHL ex 3 II ACAGGTAGTTGTTGGCAAAGC CCTAAACATCACAATGCCTAG
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4.4.2. MSI analysis (II, III)
Fluorescently labeled microsatellite marker primers (D3S1038 and D3S3659) were used
to analyze possible loss of VHL in chromosomal location 3p in two RCCs of the Spanish
patient (study II). The Bethesda panel (BAT25, BAT26, D2S123, D5S346 and D17S250), a
marker set recommended for MSI analysis by the National Cancer Institute workshop on
microsatellite instability in 1997 (Boland et al., 1998), was used in studying the link
between HIF1  and MSI (study III). The amplified fragments were assessed with
ABI3730xl DNA Analyzer (Applied Biosystems) and the results were analyzed with
GeneMapper 4.0 (Applied Biosystems).
4.5. Expression analyses
4.5.1. Quantitative real-time PCR (IV)
RNA from cell lines was collected from 6-well plates and isolated with RNeasy mini
purification columns (Qiagen, Heiden Germany). Reverse transcription of RNA to cDNA
was performed with M-MLV enzyme (Promega, Madison, WI, USA).
A quantitative real-time PCR with a TaqMan chemistry and GeneAmp® 5700 Sequence
Detection System (Applied Biosystems, Foster City, CA) was used in the analysis of FH
(exon 1) and FHv (exon 1b) expression in human tissues and cell lines (see 4.1.4.2. and
4.7.1). All primer and probe combinations were designed to span exon-exon junctions
using a Primer Express 3.0 (Applied Biosystems). The human housekeeping genes
phosphoglycerokinase or beta-actin were used in normalization of the relative mRNA copy
numbers within each sample (ABI PRISM 5700 Sequence Detection System User’s
Manual, Applied Biosystems).
4.5.2. Immunoblotting (IV)
To study the translation initiation site of FHv, HEK293 cells were transfected with
various FHv-GFP constructs (see 4.6.) and after 24-hour incubation, proteins were
extracted with an M-PER cell lysis reagent (Pierce, Rockford, IL, USA). A
spectrophotometric bicinchoninic acid (BCA) (Pierce, Rockford, IL, USA) method was
used to determine the protein concentration of the samples. Twenty-five µg of protein
were loaded in a precast 10% Tris-HCl polyacrylamide gel (BioRad, Hercules, CA, USA)
and detected with an FH antibody (dilution 1:500; Nordic Immunology, Tillburg, The
Neatherlands) and an ECL PlusTM Western blotting system (Amersham Biosciences, UK
Ltd, Buckinghamshire, UK).
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4.5.3. Immunohistochemistry (II, III)
The renal tumors of the Spanish patient (study II) were characterized by
immunohistochemical stainings of FH (dilution 1:1000; Nordic Immunology, Tillburg,
The Neatherlands), vimentin (1:1500; Dako, Glostrup, Denmark), CD10 (1:50;
Novocastra, Newcastle, UK), EMA (1:500; Dako), S-100 (1:2000; Dako), and CK8 (1:100;
Enzo Life Sciences, Farmingdale, NY), AE1/AE3 (1:700; Dako) and CK7 (1:300;
Novocastra). FH was detected with a Powervision+ detection kit (Immunovision,
Springdale, AR, USA) and the other proteins were detected with an EnVisionTM detection
system (Dako, Copenhagen, Denmark). The staining result was scored as negative (-),
light (-/+) or positive (+).
HIF1  and MSH2 protein expression was analyzed in HLRCC and HPGL tumors (see
4.1.3.) in study III. HIF1  was detected utilizing a monoclonal HIF1  antibody (dilution
1:100, clone 54, BD Biosciences, Franklin Lakes, NJ, USA) and a Powervision+ detection
kit (Immunovision). Nuclear HIF1  staining was scored as 0, 1, 2, and 3 describing a
negative staining, positive staining in 1-10% (weak), 10-50% (moderate), or >50% (high)
of the cells in the specimen, respectively. A specimen from an ischemic bowel displaying
a high HIF1  protein expression was used as a positive control. MSH2 staining (1:600,
Santa Cruz Biotechnology Inc, CA, USA) in HLRCC tumors was assayed in a LabVision
autostainerTM (Labvision Freemont, CA, USA). The TMA slide with HPGL tumors was
stained for MSH2 (1:75, clone GB12, Calbiochem, Cambridge, MA, USA) in a Dako
Techmate 500+ autostainer. In both sample sets the detection was performed with an
EnVisionTM detection system (Dako). The MSH2 staining was scored as negative (-) or
positive (+).
The tissue sections used for the IHC were derived from paraffin-embedded specimens
and were of four to five µm in thickness. In all the applications, diaminobenzidine (DAB)
was used as a chromogen and haematoxylin as a counterstain.
4.6. Constructs (IV)
The  cDNA  of FH and FHv was cloned into a pCI-neo Mammalian Expression Vector
(Promega Corporation, Madison, WI, US) and a pEGFP-N3 vector (BD Biosciencies
Clontech, Mountain View, CA, US). The cloning primers are listed in Table 5. For
identification of the translation initiation codon of FHv, several constructs with different
putative initiation sites were created in the basic FHv-pEGFP vector (FHvctg1ccc,-GFP,
FHvctg2ccc,-GFP, FHvctg1atg,-GFP, FHvctg2atg-GFP, FHvatg1ccc-GFP, FHvatg2ccc-GFP, and
FHvatg3ccc-GFP) by a site-directed mutagenesis (QuickChange® Site-Directed Mutagenesis
Kit, Stratagene, La Jolla, CA). In addition, a construct without exon 1 or 1b and with an
additional ATG at the beginning of the exon 2 was created (FHno-signal-GFP) (see study IV,
Figure 4a). All the constructs were verified by direct sequencing.
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Table 5. Cloning primers for cDNA constructs











pEGFP vector TTTGAATTCGCTGGAATGGCAAGCCAAAATTC TTTGGATCCCTTTGGACCCAGCATGTCCTT
*With the primers the FHv sequence starts from the first CTG in exon 1b (see also Figure 5). **FH cDNA inserted
into the pCi-neo vector was digested out from the pEGFP vector.
4.7.  Cell culture (IV)
4.7.1. Cell lines
HEK293 (human embryonic kidney cells; CRL-1573, American Type of Culture
Collection, ATCC), HeLa (cervical cancer cells; CCL-2, ATCC), and SK-UT-1B (uterine
leiomyosarcoma cells; HTB-115, ATCC) were utilized in studying the characteristics of
FHv. In addition, 12 more cell lines were studied for FHv expression in stress conditions
including ATCC lines SV7tert, SK-LMS-1, A704, LNCaP, DU-145, DLD-1, RKO, SW-480,
HCT-116, SK-UT-1, MES-SA, and line LS174T from European Collection of Cell Cultures
(ECACC). These cells originated from ULMS, RCC, prostate cancer, colorectal cancer, or
from a normal kidney.
4.7.2. Culture conditions (normal and stress conditions)
Cell lines were cultured in medias recommended by ATCC or EACC, and were
supplemented with penicillin-streptomycin (100 U/ml and 0.1 mg/ml) (Sigma-Aldrich)
and 10% FBS (5% FBS for HEK293). Normal culture conditions were set as 37ºC, 5% CO2,
and 21% O2.
Various stress conditions including glucose or serum deprivation, hydrogen peroxide
exposure, hypoxia and heat shock were used to test induction of FHv. The glucose and
serum deprivation was performed by culturing cells in DMEM without glucose and
either with low (0.1%) or without FBS for 24 and 48 hours. In hydrogen peroxide
exposure, cells were incubated with 200 µM H2O2 for 30 minutes. After the exposure,
incubation was continued for 24 and 48 hours in normal media. Hypoxia (1% O2, 5% CO2,
94% N2) was generated in a hypoxia incubator (Invivo2 Hypoxia Workstation 400,
Ruskinn Technology Ltd, Leeds, UK), in which cells were cultured for 24, 48, 72, and 96
hours. The heat stress was created at a temperature of 42°C in a regular culture incubator
for 0.5, 1, and 2 hours.
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4.8.  Transfection and immunofluorescence (IV)
To monitor FH and FHv protein distribution in a cell, HEK293 cells in approximately
70% confluence were transfected with GFP-constructs (FH-GFP, FHv-GFP, FHvatg1ccc-
GFP, FHvatg2ccc-GFP, FHvatg3ccc-GFP) (see 4.6.) using a FuGENE 6 reagent (Roche Applied
Science, Indianapolis, IN). After 24 hours from transfection, the cells were fed with a
MitoTracker (100 pmol/ml, MitoTracker Red CMXRos; Molecular Probes/Invitrogen,
Carlsbad, CA, USA) and fixed with 4% paraformaldehyde. The immunodetection of the
endogenous FH protein was performed on fixed cells with a porcine FH antibody (1:100;
Nordic Immunology, Tilburg, Netherlands) and a FITC-conjugated goat anti-rabbit IgG.
Nuclei were visualized with a Hoechst (33258) stain (Sigma-Aldrich). The subcellular
distribution of the proteins was monitored using a Leica TCS SP1 confocal microscope or
Axioplan upright epifluorescence microscope.
4.9. FH enzyme activity assay (IV)
To measure the enzyme activity of FHv, HEK293 cells were transfected with FHv-pCi-
neo and for comparison with a FH-pCi-neo construct. The method, originally described
by Hatch in 1978, is based on the detection of the reduced nicotinamide adenine
dinucleotide phosphate (NADPH) produced in a reaction containing fumarate, FH from
the cell sample under investigation, malate dehydrogenase (MDH), and oxidized
nicotinamide adenine dinucleotide phosphate (NADP). The NADPH in the assay mix is
produced along with oxaloacetate through the following reaction:
In short, fumarate mixed with FH produces malate, which is oxidated into oxaloacetate
by malate dehydrogenase (MDH) simultaneously reducing NADH to NADPH. The
production of NADPH is detected spectrophotometrically (A340),  and the FH activity is
quantified as the amount of NADP consumed per minute per mg of total protein in the
sample.
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4.10. In silico  analyses (IV)
Following electronic databases and web-based tools were utilized in the analyses of the
alternative transcript of FH (FHv) (Table 6).
Table 6. Electronic tools utilized in the study of alternative FH transcript (FHv)
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5.1. Novel clinical features of HLRCC
5.1.1. The tumor spectrum and cancer risk in Finnish HLRCC families (I)
An extended search for the family members and their cancer status was performed for
the seven Finnish HLRCC and one FHD families (Table 3). Altogether 868 family
members were identified (Appendix 1). A set of members of the eight families (n=256)
was included in the cancer risk analysis determined by a standardized incidence ratio
(SIR). The comparison of the cancer cases in the families and in the general Finnish
population elicited a higher incidence of renal cell cancer (RCC) and uterine
leiomyosarcoma (ULMS). The incidence of RCC was 6.5-fold (95% CI: 2.1 to 15.0) and 71-
fold (95% CI: 8.6 to 260) for ULMS. SIR for common cancer types (breast, prostate, lung,
and colorectal carcinoma) and hematopoietic and lymphoid malignancies was also
calculated but no higher incidence was observed in the HLRCC/FHD families.
DNA for the FH mutation analysis was available from 98 members of the eight families
and 54 were found as FH mutation positive. Of these, 26 were diagnosed with cancer
(Table 5, Appendix 1). The number of cancer cases was particularly high in young age
groups since 14 cases (43%) were diagnosed at less than 44 years of age. In comparison,
in the mutation-negative individuals, all but one (15/16, 94%) cancer cases were
diagnosed at the age of 45 or later. The result, however, was significant (p=0.009) only if
the probands’ cancers were included in the statistical comparison. As also seen in the SIR
analysis, the most prominent tumor types in the FH mutation carriers were RCC (n=12)
and ULMS (n=5). In addition, several cases of breast cancer, and hematopoietic and
lymphoid malignancies were observed. Four FH mutation-positive individuals had more
than one malignancy. Two of them had ULMS and breast cancer, one had ULMS and
RCC, and one had RCC and basal cell carcinoma. Strikingly, the other ULMS patient
with breast cancer was also affected with multiple myeloma and non-Hodgkin’s
lymphoma. Tumors including RCCs (n=12), ULMSs (n=3), breast cancers (n=3), and
single cases of bladder cancer, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, chronic
lymphatic leukemia, esophageal cancer, and basal cell cancer were analyzed for
inactivation of the wild-type FH allele. The analyses showed somatic inactivation of the
wild-type FH allele in the majority of the analyzed RCCs (10/12, 83%), all the ULMSs
(3/3), breast cancers (3/3), and bladder cancer (1/1) (Table 5).
The radiological reports on the pelvic area, available from 33 individuals, revealed
existence of some benign tumors. Kidney cysts and adrenal gland adenomas were
observed in 42% (14/33) and 12% (4/33) of these individuals, respectively. One liver
hemangioma was detected as well. Moreover, reports about four atypical uterine
leiomyoma cases and one patient operated frequently for benign fibrocystic lesions of the
breast were found.
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Table 5. Cancer cases in FH mutation carriers
Cancer n Age at diagnosis (median) Somatic second hitdetected/analyzed
RCC 12* 26, 32, 33, 35, 36, 39, 42, 48, 49, 68, 71, 90 (40.5) 10/12**
ULMS 5* 27, 30, 32, 35, 39 (32) 3/3**
Breast cancer 4* 50, 53, 55, 61 (52.5) 3/3
Bladder 1 71 1/1
Non-Hodgkin’s lymphoma 1 63 0/1
Hodgkin’s lymphoma 1* 24 0/1
Chronic lymphatic leukemia 1 48 0/1
Esophagus cancer 1 53 0/1
Basal cell cancer 2 70, 83 0/1
Multiple myeloma 1* 61 NA
Prostate cancer 1* 63 NA
Liver/bile duct cancer*** 1 82 NA
Unknown origin 1 42 NA
NA, not analyzed. *These lesions, except one of the breast cancers were previously reported by Launonen et al.
(2001) and Kiuru et al. (2002 & 2005). **Seven RCCs and two ULMSs were analyzed for FH (1q42-q44) LOH by
Launonen et al. (2001), Kiuru et al. (2001), and Tomlinson et al. (2002). ***Obligate mutation carrier.
5.1.2. Conventional renal cell cancer in HLRCC (II)
The Spanish RCC case was originally admitted to hospital because of unusual uterine
bleeding. This 23-year-old female patient was then diagnosed by ultrasound to have a
myomatous uterus and incidentally also a bilateral renal mass. A computed tomography
(CT) scan confirmed the lesions suggestive of RCC. The lesions were subsequently
removed, the right-side tumor via a partial and the left-side tumor via a radical
nephrectomy. The right-side tumor was 2.3cm in diameter and it showed cystic,
papillary and trabecular areas. It displayed papillary morphology, abundant eosinophilic
cytoplasm, and was classified Fuhrman grade 2 with medium-sized nuclei and small
nucleoli. The left-side tumor was 13cm in diameter and showed solid, tubular, and cystic
areas and it displayed conventional (clear) cell type histology with a moderate
cytoplasm. The Fuhrman grade was 2 with small nuclei and inconspicuous nucleoli. The
IHC profile of the tumors was compared with three RCCs from the Finnish HLRCC
FAM-1. EMA, S-100, vimentin, CK7, and AE1/AE3 stained similarly in the Spanish
tumors and in the FAM1 tumors (EMA, however, negative in one FAM1 tumor). As an
exception, the Spanish RCCs were positive in CD10 and CK8 staining. In addition, the
right-side tumor differed from others being negative for AE1/AE3 and positive for FH.
The positive staining for vimentin and CD10 differentiated the clear cell tumor from
chromophobe RCC, which also displays a clear cytoplasm. Two ULMs were later
removed by myomectomy. These tumors were of 8.5 and 2.8 cm in diameter and
displayed nuclear atypia and a low mitotic index.
The patient and her mother were screened for FH mutations and were found to carry a
novel missense mutation N330S (AAC>AGC), which results in the change of the amino
acid asparagine into serine. The search for inactivation of the wild-type FH allele in the
tumors revealed loss of the gene in the left-side conventional renal tumor but not in the
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right-side papillary tumor. Since mutations in the VHL gene on chromosome 3p lay
commonly under clear cell tumors, the left-side tumor was analyzed for mutations in
VHL and for LOH in 3p. No alterations at the VHL locus were observed.
5.2.  Characteristics of FH  and SDH
5.2.1. HIF1  and mismatch repair in FH and SDH tumors (III)
HIF1  stabilization in the HLRCC tumors (11 RCCs, 12 ULMs, and 1 ULMS) as well as in
the 63 PGLs/PHEOs with an SDHB/C/D mutation (on the TMA) was studied with IHC.
In the HLRCC samples, HIF1  was present in a moderate or high proportion of the
tumor cells (scores 2 and 3, respectively) in 67% (16/24) of RCC and ULM/ULMS
specimens (Table 7). In general, the staining was mainly nuclear but some cytoplasmic
positivity was observed in a few specimens. The normal renal glomeruli and tubular
epithelium stained with a low intensity and in some of the specimens a weak positive
staining was observed in the normal myometrium. The PGLs with an SDHB/C/D
mutation showed in 79% of the cases (48/61) moderate or high levels of HIF1 . One
(1/62) PGL could not be analyzed. The non-familial PGLs (n=35) showed a similar HIF1
stabilization in 71% (25/35) of the samples. Of note, all the PHEOs (17/17) displayed no
or low HIF1  expression (Table 7).




 0 1 2 3 no result
HLRCC tumors
    RCC 11 1*/11 2/11 1/11 7/11
    ULM 12 1/12 3/12 2/12 6/12
    ULMS 1 1/1
Total (%) 24 2/24 (8.0) 6/24 (25) 3/24 (12.5) 13/24 (54)
    Non-familial ULM (%) 4 1/4 (25) 2/4 (50) 1/4 (25)
Pheochromocytomas
   SDHD 1 1
   NF 2 2
   VHL 1 1
   RET 3 3
   Total (%) 7 0/7 (0) 7/7 (100)
   Non-familial** (%) 10 2/10 (20.0) 8/10 (80.0)
Paragangliomas
   SDHB 2 2
   SDHC 1 1
   SDHD*** 59 3 10 16 29 1
   Total (%) 62 3/62 (4.8) 10/62 (16.1) 17/62 (27.4) 31/62 (50.0) 1/62 (1.6)
   PGL2**** (%) 3 2/3 (66.7) 1/3 (33.3)
   Non-familial** (%) 35 4/35 (11.4) 6/35 (17.1) 11/35 (31.4) 14/35 (40)
HIF1  staining  scoring:  0  =  negative,  1  =  1-10%  of  cells  positive,  2  =  10-50%,  3  =  >50%.  *Necrotic  tissue.  **No
SDHB/C/D mutation/not analyzed. ***Including one tumor originating from the Zuckerkandl’s organ. ****Tumors
linked to the putative PGL2 gene locus (Maher and Eng, 2002).
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MSH2 protein expression by IHC was analyzed from the same set of samples. The
HLRCC samples and the samples on the TMA were analyzed with 96%, and 85%
success, respectively. In the remainder of the PGLs/PHEOs, absence of tumor tissue in
the specimen, negative staining in both normal and tumor tissue, and detaching of the
specimen were used as exclusion criteria. The negative staining in the normal tissue
probably resulted from technical issues or a low proliferation rate, typical for this tissue.
All the analyzable specimens showed normal positive MSH2 staining in the tumor.
Microsatellite instability in the HLRCC tumors (10 RCCs, 12 ULMs, and 1 ULMS) as well
as in 27 PGLs (18 SDHD,  2 PGL2, and 7 non-familial) was studied with the Bethesda
panel microsatellite markers with an 88% success rate. All these tumors were
microsatellite stable.
5.2.2. Characteristics of the alternative transcript of FH (FHv) (IV)
5.2.2.1. Structure and mutation status of the FHv transcript
An AceView gene database (http://ncbi.nih.gov/IEB/Research/Acembly/index.html) first
released a 414 bp FH sequence (GenBank accession no. AI971779.1) containing exon 2, a
part of exon 3, and an upstream sequence (exon 1b) that mapped the intronic region
between exons 1 and 2. When the transcript, named FHv, was amplified, it was in full
length found to contain exon 1b, which replaces exon 1 encoding the mitochondrial
signal peptide of FH, and exons 2 to 10 identical to FH.
In silico methods were utilized to search the FH variant sequence for a 5’ extension of
exon 1b, CpG island, core promoter, evolutionary conserved transcription factor binding
sites such as heat or hypoxia response elements, or nuclear localization signal with
negative results. A transcript including exon 1b was not found in other species, but a
similar kind of variant lacking the first exon encoding the mitochondrial signal peptide
was found in another gene of TCA cycle, SDHB (http://vega.sanger.ac.uk/index.html).
A set of human DNA samples (n=139) was screened for mutations in exon 1b. The
mutation analysis revealed no alterations in exon 1b or its flanking sequences.
5.2.2.2. Increased expression of FHv by prolonged hypoxia and heat shock
FHv was shown to be widely expressed in fetal and adult human tissues (tissue cDNA
panels). However, the expression of FHv was clearly lower compared to mitochondrial
FH, the average difference being approximately 300-fold.
The effect of different stress conditions on the expression of FHv was studied with
HEK293 and HeLa cells. The glucose and serum deprivation, H2O2 treatment, or hypoxia
(1% O2) for up to 48 hours had no detectable effect on endogenous FHv or FH mRNA
expression levels. However, more prolonged (72 to 96 hours) hypoxia somewhat
increased FHv expression. Therefore, 13 additional cell lines were analyzed in long-term
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hypoxia. A similar trend was observed in approximately half of the other cell lines
studied. Especially one cell line, a uterine leiomyosarcoma line HTB115, displayed a
clear (four-fold) increase in FHv mRNA levels after 72-96 hours exposure compared to
the untreated control cells. Subsequently, HTB115 cells were analyzed for FHv response
at a temperature of 42°C. The heat shock of 0.5, 1, and 2 hours resulted in a 3-, 6-, and 9-
fold increase in FHv expression, respectively (Figure 4). A two-fold and three-fold
increase after two hours of exposure was observed in HEK293 and CRL2461 cells, the
other cell lines analyzed. For reference, FH mRNA levels sustained approximately at a
basal level during hypoxia and heat shock.
Figure 4. Relative  (beta-actin
normalized) mRNA expression
of FHv (dark bars) and FH (light
bars) in HTB115 cells after
hypoxia (1% O2) and heat shock
(42°C). The results are shown as
a ratio of the expression of stress
treated cells and non-treated
control  cells  (the  ratio  of  1  is
obtained if there is no difference
between treated and control
samples); a) FHv mRNA
expression increased 4-fold
during  72-96  hours  exposure  in
hypoxia when compared to the
control cells; b) In  heat  stress,
FHv expression increased
during  two  hours  exposure  up
to 9-fold. No significant changes
were observed in the expression
of FH in either condition. Since
the expression level of FHv in
general  is  much  lower  than  of
FH (in HTB115 cells over 100
times), the expression levels of
FHv and FH were analyzed
individually and thus are not in
the figure comparable with each
other.
5.2.2.3. Translation, subcellular distribution, and activity of FHv
To determine the FHv translation initiation site, different FHv cDNA constructs (pEGFP-
based) were expressed in HEK293 cells. FHv-GFP resulted in three protein products in a
Western blot, of which the middle one was the faintest. Because exon 1b does not contain
any ATG, two in frame CTGs (in exon 1b) and three ATGs (two in exon 2 and one in
exon 3) were considered as putative translation initiation sites (Figure 5). First, both the
50
CTGs were separately mutated to CCC (constructs FHvctg1ccc-GFP and FHvctg2ccc-GFP) and
then to ATG (FHvctg1atg-GFP and FHvctg2atg-GFP) in order to respectively inhibit or
enhance possible translation. With this setup, none of the three bands vanished after the
mutation of the CTGs to CCCs. Moreover, when the CTGs were mutated to ATGs,
additional bands with a higher molecular weight appeared. Therefore, the possibility of
translation of FHv from 1b was excluded. Subsequently, when the three ATGs in exons 2
and 3 were separately mutated to CCCs (FHvatg1ccc-GFP, FHvatg2ccc-GFP, and FHvatg3ccc-
GFP), each of the three bands vanished one by one indicating the translation of FHv to be
initiated from these codons. The reading frame thus remains the same as that of FH.
Figure 5. Sequence of FHv showing exons 1b, 2 and 3 (exons are distinguished from each other with
the gray shading). The putative initiation codons are in bold and named referring to the terms used in
the expression constructs. Nine bases upstream of “CTG1” is an inframe stop codon (TAG).
The subcellular distribution of the FHv protein was studied by expressing a GFP-tagged
FHv construct in cells. FHv-GFP distributed in the nucleus and cytosol. No changes were
seen in the localization when the three ATGs in exons 2 and 3 were separately
inactivated. For reference, the construct lacking exon 1 was present only in the cytosol.
Endogenous FH and FH-GFP localized to the mitochondria. In addition, cytosolic
protein was also observed in a subset of cells expressing FH-GFP.
The FH enzyme activity of FHv was determined by an enzyme kinetics assay with a
spectrophotometrical detection. The basal level of FH activity of the cells used (HEK293)
was 36 nmol/min/mg of protein. Overexpression of FH (from pCi-neo vector) resulted in
an increased activity up to 390 nmol/min/mg of protein. However, overexpression of




6.1. Cancer risk and tumors associated with HLRCC (I)
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a tumor predisposition
syndrome caused by heterozygous germline mutations in the tumor suppressor fumarate
hydratase, FH. The most prominent feature of HLRCC is the leiomyomatosis of the skin
and uterus, and approximately in every fifth family there are cases of renal cell cancer
(Launonen et al., 2001, Tomlinson et al., 2002, Toro et al., 2003, Alam et al., 2003 & 2005b,
Kiuru et al., 2005, Chan et al., 2005, Badeloe et al., 2006, Chuang et al., 2005 & 2006, Wei
et al., 2006, Refae et al., 2007). The majority of RCC cases have been reported in North
America and Finland. In the UK, which has several HLRCC families, only two RCC cases
have been found. This number may, however, be somewhat biased as many families in
the UK have been identified based on the leiomyomatosis phenotype. The malignant
counterpart of ULM, uterine leiomyosarcoma (ULMS) in association with germline
mutations in FH is detected only in the Finnish population (Launonen et al., 2001, Kiuru
et al., 2002, Ylisaukko-oja et al., 2006a). Of note, the diagnosis criteria of ULMS have been
become more stringent during the recent years. Therefore, in comparison with the
calculated risk obtained in study I, a revised, lower risk estimate is presented in section
6.2.2. in the context of the histopathological features of uterine smooth muscle tumors.
Due to the reduced penetrance of the malignant tumors in HLRCC and their
concentration on certain families and populations, it is possible that some tumors that
are less central in the phenotype may not have been identified. Moreover, the actual risk
of cancer has been remained unclear. Hence, we aimed to define the cancer risk, and to
identify possible additional malignancies among FH mutation carriers utilizing the
Finnish HLRCC/FHD families. The resources for hereditary cancer research are
exceptional in Finland as clinicians are obliged to report all the cancer cases to the
Finnish Cancer Registry, of which coverage and quality have been estimated to be very
high (Teppo et al. 1994). Moreover, the population-based verified genealogy data in the
Finnish Population Register Centre facilitates research of this type. Through the
extensive search for members of the seven Finnish HLRCC families and the FHD
kindred, altogether 868 individuals were identified. Of the 98 individuals analyzed for a
germline FH mutation, 54 were found to be mutation carriers. Cancer was observed in 27
patients, of which four were affected with more than one malignancy.
The cancer risk in HLRCC/FHD family members was assessed from a sample of 256
individuals with the Finnish Cancer Registry based analysis. These kinds of analyses are
typically sensitive to the ascertainment criteria of the families and selection bias. This
was avoided by excluding all the cancers in the index patients and other individuals
utilized in the HLRCC family identification from the analysis and by including only the
completely traced generations. The analysis revealed 6.5-fold incidence (SIR,
standardized incidence ratio) of RCC (95% CI; 2.1-15.0), being the first calculated
estimate for cancer risk in HLRCC. All the 12 patients affected with RCC were FH
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mutation carriers covering 22% (12/54) of all the individuals observed with a germline
FH mutation. Typical of a hereditary tumor predisposition is that tumors arise at a
young age. The age at RCC diagnosis varied between 26 and 90 years of age (average
47.5, median 40.5), whereas the average diagnosis age for RCC in the Finnish population
is 64 in males and 69 in females (Pukkala et al., 2006; Finnish Cancer Registry 1994-2003
statistics). Of note, in the Finnish HLRCC families 75% (9/12) of the RCC cases were
found in female mutation carriers. However, when the cases in other populations (24
males and 21 females; Toro et al., 2003, Alam et al, 2003 & 2005b, Chan et al., 2005,
Chuang et al., 2005 & 2006, Wei et al., 2006, Badeloe et al., 2006, Refae et al., 2007, study
II) are counted, the female distribution evens out to 53% (30/57). In comparison, in the
general population RCC is seen with a 1.6 to 2 -fold male predominance (Finnish Cancer
Registry; http://www.cancerregistry.fi/statistics, Wallen et al., 2007, Jemal et al., 2007). In
the SIR analysis, ULMS was the only other tumor type in addition to RCC that obtained
significant risk values. The incidence of ULMS was calculated as 71-fold but as based on
a few tumors, the 95% confidence interval was quite broad (95% CI; 8.6-260) (see also
6.2.2.). Altogether five ULMS tumors were observed in the female mutation carriers
(5/33, 18%) with diagnosis age between 27 and 39 years (average 33, median 32). The age
of onset in these cases is very early, the median age for ULMS reported between 50 and
55 years (Major et al., 1993, Gadducci et al., 1996). The risk estimates for RCC and ULMS
were, however, obtained from a high risk population and cannot therefore be directly
conveyed to other populations.
All the available tumors from the FH mutation carriers were analyzed for biallelic
inactivation of the gene. Eighty-three percent (10/12) of the RCCs displayed loss or a
point mutation in the wild-type allele. Interestingly, all the breast cancers (3/3) and one
bladder cancer (1/1) analyzed were detected with the loss of the wild-type allele
indicating that they might result from a germline FH mutation. Moreover, according to
genomic copy number analyses (array CGH) the loss of 1q (the FH locus at 1q43) is not a
typical alteration in sporadic breast and bladder cancers (Sandberg, 2002, Miller et al.,
2003, Blaveri et al., 2005, Mao et al., 2005, Climent et al., 2007, Chin et al., 2007). One
malignant and two benign tumors of the breast and one bladder cancer have also been
observed in FH mutation carriers in the UK and North America (Alam et al., 2005b, Wei
et al., 2006). However, data on the biallelic inactivation of FH in these types of tumors
have not previously been reported. The age at diagnosis of the breast cancers in the
Finnish patients were on average somewhat younger (50, 53, 55, 61; median 52.5, average
55) than in general. On average Finnish breast cancer patients are diagnosed at 61 years
of age (Pukkala et al., 2006; Finnish Cancer Registry statistics 1994-2003). Notable is that
the diagnosis age of breast cancer has lowered significantly since population screenings
by mammography started in 1987 (Pukkala et al., 2006).
In addition, several other tumor types were detected in the Finnish HLRCC patients, for
example prostate cancer and hematological and lymphoid malignancies (Table 5,
Appendix 1). In the FH germline mutation carriers in other populations a case of skin
leiomyosarcoma, two adult Leydig cell tumor cases (with biallelic loss of FH), a
malignant brain tumor, an ovarian cyst and gastric polyp (in one patient), Cushing
53
syndrome, and cerebral cavernomas have been reported in addition to the classic
HLRCC manifestations (Toro et al., 2003, Alam et al., 2005b, Matyakhina et al., 2005,
Carvajal-Carmona et al., 2006, Varol et al., 2007, Campione et al., 2007). Some extensive
screenings have also been performed to study the role of FH in the genesis of different
tumor types. The sample sets have included familial and sporadic tumors of the breast,
prostate and ovaries (Kiuru 2002 & 2005, Bevan et al., 2003, Lehtonen 2003 & 2004,
Ylisaukko-oja et al., 2006b). Moreover, sporadic bladder, testicular, lung, colorectal, and
head and neck squamous cell carcinomas as well as melanomas and PHEOs have been
evaluated for FH mutations (Lehtonen et al., 2004). In these screenings, two patients
affected with ovarian cystadenoma were identified with germline FH coding region
alterations (Ylisaukko-oja et al., 2006b). Otherwise only some FH polymorphisms were
found. The role of FH in the tumorigenesis of sporadic CLM and ULM, and sarcomas
including uterine tumors have been studied in several approaches but only a few ULMs
and a soft tissue sarcoma of a lower limb have emerged with the somatic inactivation of
FH (Kiuru et al., 2002, Barker et al., 2002, Lehtonen et al., 2004, Gross et al., 2004,
Ylisaukko-oja et al., 2006a). Thus, FH mutations occasionally contribute to tumorigenesis
of sporadic ULMs but have a limited role in the genesis of tumors other than the HLRCC
spectrum. The analyses have, however, incidentally revealed FH germline carriers,
including probands of the Finnish families FAM6 and FAM7 (with ULMS and CLM,
respectively) as well as another patient with ULMS (Kiuru et al., 2002, Ylisaukko-oja et
al., 2006a). In the recent ULMS case, however, allelic loss of FH in the tumor failed to be
proven (Ylisaukko-oja et al., 2006a).
Previously in the heterozygous FH mutation carriers in FHD families only three cases of
CLM have been reported (Tomlinson, et al., 2002, Maradin, 2006). In our analyses, the
bladder cancer and one of the breast cancers with biallelic inactivation of FH were found
in the FHD family. These results indicate potential for malignancies also in these
families, although the most common tumor types (leiomyomas and RCC) were absent.
The variety in the phenotypes, between HLRCC and FHD and even within HLRCC
families in the issue of RCC, has been widely discussed. Since no clear genotype-
phenotype correlation has been observed, the possibility of another genetic factor or
factors modifying the morbidity risk has been considered as a strong option but no
evidence supporting this has been attained so far.
Cutaneous or uterine leiomyomas were not assessed in this particular approach but
some other benign tumors were identified, such as adrenal gland adenomas (n=4) and
kidney cysts (n=14). The incidence of adrenal tumors seemed to be higher in HLRCC
(found in 12% of the mutation carriers) compared to only 0.5-2% for the population in
general (Barzon et al., 2003). Though kidney cysts are generally common, interestingly,
the incidence of these lesions was higher in the FH mutation carriers than in the general
population in regard to individuals under 40 years of age. The incidence was 36% in the
mutation carriers vs. 4.6-8.2% (detection method ultrasound or computed tomography,
respectively) in the general population (Terada et al., 2002, Carrim & Murchison, 2003).
Moreover, some of the Finnish HLRCC patients’ RCCs showed cystic features. Recently,
kidney-specific Fh1 knockout mice were shown to develop large and numerous kidney
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cysts which finally led to a polyuric renal failure. The cyst formation was suggested to
result from an increased cell proliferation due to activation of the hypoxia pathway
(Pollard et al., 2007). Since both HLRCC and VHL patients display renal cysts, they have
been postulated as premalignant lesions (Mandriota et al., 2002, Pollard et al., 2007, see
also 2.2.2.). Consequently, the tumorigenic pathway in an FH-deficient kidney has been
suggested to be comprised of a sequence from a simple cyst through a dysplastic cyst to
a carcinoma. In this hypothesis, FH inactivation is an initiating event, and additional
genetic events would take place along with the transformation process. In the Fh1
knockout mice the lethal renal failure, however, disables the monitoring of possible renal
cancer formation (Pollard et al., 2007).
6.2. Histopathological features of HLRCC-associated tumors (I,  II,
unpublished data)
Neoplasms are assessed with variable methods including evaluation of tumor size and
site, as well as possible invasion. Moreover, histopathological classification (i.e.
morphological features), as well as genetic determinants and specific protein expression
patterns are utilized in the main objectives of tumor classification, the prediction of the
clinical behavior of the tumor, prognosis, and responsiveness to therapies.
6.2.1. Renal tumors
Epithelial renal neoplasms include a variety of tumor types with different
histopathological and genetic features (see also 2.2.). The distinct morphology of the
renal tumors in the first HLRCC family was a central observation when the syndrome
was discovered. The tumors were found with a papillary growth pattern, the cells were
large with abundant cytoplasm and displayed a high Fuhrman nuclear grade (3 or 4)
with large and prominent “owl-eye like” nucleoli (Launonen et al., 2001). Mostly the
tumors resembled the type 2 papillary histology described by Delahunt and Eble (1997).
These unique characteristics have subsequently been used in the identification of new
HLRCC families, as in the case of the Finnish FAM2 (Launonen et al., 2001). Later on,
four cases of renal collecting duct carcinomas (CDC) and one oncocytoma were also
reported in the context of a germline FH mutation (Alam et al., 2003, Toro et al., 2003,
Wei et al., 2006). In study II, the tumors of the young Spanish HLRCC patient with a
bilateral RCC resembled only partly the previously observed HLRCC-associated RCCs.
The right-side tumor had a cystic and papillary structure and large cells with abundant
eosinophilic cytoplasm. However, the Fuhrman grade was low (2) and the nuclei were
only medium-sized and the nucleoli small. The left-side tumor displayed tubular
structure and clear cells with a solid and acinar pattern, and a low Fuhrman grade (2)
with small nuclei and inconspicuous nucleoli. Curiously, the more exceptional left-side
tumor displayed LOH at the FH locus and thus connected the conventional (clear cell)
type RCC to a germline FH mutation. Biallelic inactivation of FH in the right-side tumor
could not be detected with conventional sequencing or IHC.
55
Recently, Merino and co-workers evaluated a set of North American HLRCC renal
tumor material for their pathologic features. Of the 40 tumors, the majority displayed a
papillary architecture and some showed a tubulo-papillary, tubular, solid, or mixed
pattern. In a few cases, clear cell components were seen in association with papillary and
solid elements. All the tumors were classified with a high Fuhrman grade. Subsequently,
common to all the histological components, the presence of a large nucleus with a
prominent eosinophilic nucleolus surrounded with a clear halo was seen (Merino et al.,
2007). However, the cells of the both RCCs in the Spanish patient had inconspicuous
nucleoli related to a low Fuhrman grade. To exclude the influence of possible underlying
VHL loss on the tumor phenotype, mutation and LOH analysis at VHL locus was
performed with negative results. The FH germline alteration found in the patient and the
patient’s mother was a novel missense mutation (N330S). The type or site of a mutation
could be postulated to affect on the appearance of a tumor. CDC is also representing a
minority type of RCC in HLRCC. However, at least in the case of CDCs, any specific FH
mutation type does not seem to define the formation of this tumor type (Alam et al.,
2003, Toro et al., 2003, Wei et al., 2006). Moreover, of the CDC-associated FH mutations,
R58X has been seen in the formation of papillary RCCs as well (Wei et al., 2006).
The HLRCC-associated renal tumors are highly aggressive already as small lesions
compared to the types in other hereditary syndromes. Thus, it is relevant to find clear
identifiers for HLRCC-associated renal tumors and to make pathologists aware of this
entity (Grubb et al., 2007). No clear immunophenotype has been established for the
HLRCC tumors, but absence of CK7 and UEA-1 expression has been proposed as one
alternative for facilitating the differential diagnosis (Merino et al., 2007). In our
experience, at least the lack of CK7 expression is common to the Finnish HLRCC renal
tumors and also to the Spanish patient’s tumors with the divergent morphological
appearance. Moreover, utilization of FH IHC in the differentiating diagnosis of early-
onset RCC is a potential alternative as seen in our study (II). The aggressive phenotype
also elicits the importance of establishing optimal strategies for the resection of the
tumors, follow-up, and screening the FH mutation carriers (Grubb et al., 2007).
6.2.2. Uterine tumors
Smooth muscle tumors (SMTs) include cutaneous, vascular, peripheral soft tissue,
gastrointestinal, and uterine tumors among others (Miettinen & Fetsch, 2006). Uterine
smooth muscle tumors (and other SMTs) can be roughly categorized as leiomyomas
(ULM, benign) and leiomyosarcomas (ULMS, malignant) based on the locality of the
tumor as well as on cytolocigal characteristics: the degree of nuclear atypia (mild,
moderate or severe), mitotic activity, and coagulative necrosis. The ordinary types of
tumors are quite simply defined. However, the overlapping features in ULMs and
ULMSs, the subjectivity of the observations, and sometimes also differences in opinions
and limited experience in some rarer cases may cause problems in the differential
diagnosis of benign and malignant uterine tumors. Therefore, sometimes, if the clinical
behavior of a tumor is truly difficult to predict, a category of tumors with “uncertain
malignant potential” can be used (Kempson & Hendrickson, 1999, Hart, 2002).
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An ordinary ULM is characterized by whorled bundles of elongated smooth-muscle cells
that are closely packed so that the tumor appears to be more cellular. The nuclei of cells
are elongated and uniform. Mitoses are absent or sparse (Robboy et al., 2000). In contrast,
ULMSs generally have high levels of mitotic activity, hypercellularity, diffuse nuclear
atypia, and coagulative tumor cell necrosis. Presently, the tumor necrosis alone,
independent from the mitotic index or the degree of atypia, is considered to be sufficient
for defining malignancy. If necrosis is absent, tumors combined with a significant
(moderate or severe) atypia and 10 mitotic figures (MF)/10 high power fields (HPF) are
considered ULMS (WHO Classification of Tumors 2003; Tumors of the Breast and
Female Genital Organs) (Table 8). Typically ULMSs are also usually larger in size (>10
cm) than ULMs and have other disturbing cross-features (Hart, 2002).
Some histological variants of ULM, including mitotically active ULM, cellular ULM, and
atypical ULM, can cause difficulties in diagnosis since they display features also typical
of ULMS. Previously in ULMS diagnosis, emphasis has been on the mitotic counts so
that any tumor with over 10 MF/10 HPF has been classified as malignant (Robboy et al.,
2000). According to the recent citeria, when neither atypia nor coagulative necrosis is
present, or when only mild atypia is present with no coagulative necrosis in a uterine
tumor, the mitotic index can be as high as 10 MF/10 HPF for defining the tumor as an
ULM. Even higher mitotic indexes can be acceptable, but >15 mitoses/10 HPF are
suggested to be classified with definitions of a limited experience (WHO Classification of
Tumors 2003; Tumors of the Breast and Female Genital Organs) or even with an
uncertain malignant potential (Miettinen & Fetch, 2006). The cellular ULM accounts for
less than 5% of ULMs and is characterized by a significantly greater cellularity compared
to the surrounding myometrium (WHO Classification of Tumors 2003; Tumors of the
Breast and Female Genital Organs). The atypia (nuclear enlargement, pleomorphism,
hyperchromatism) is probably the most subjective feature to qualify. ULMs with atypical
features have stricter limits for mitoses, the number of which still divides opinions.
Tumors with <10 MF/10 HPF and significant atypia but without coagulative necrosis are,
according to certain criteria, considered as atypical ULMs with a low (2-3%) risk of
recurrence (Bell et al., 1994, WHO Classification of Tumors 2003; Tumors of the Breast
and Female Genital Organs) and, according to those supporting the older criteria, tumors
with the same characteristics and even with <5 MF/10 HPF should be considered as
having uncertain malignant potential, and tumors with >5 MF/10 HPF as potentially
malignant (Miettinen & Fetsch, 2006) (Table 8). Of note, this group of tumors, presently
often classified as “atypical ULMs” (or bizarre, symplastic or pleomorphic ULMs), was
previously termed as in situ ULMSs (Hart, 2002).
In addition to these features of smooth muscle tumors, sometimes myxoid or epitheloid
changes can be seen in both ULMSs and ULMs. To determine the malignant potential,
these types of tumors should be especially carefully evaluated. Curiously, benign ULMs
rarely display also unusual growth patterns including intravascular, disseminating, and
metastasizing growth (Robboy et al., 2000, WHO Classification of Tumors 2003; Tumors
of the Breast and Female Genital Organs).
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Table 8. Histological  diagnostic  criteria  of  uterine  smooth  muscle  tumors  according  to  the  WHO
Classification of Tumors, 2003 (Tumors of the Breast and Female Genital Organs)
* “leiomyoma with limited experience” can also be used for defining a tumor with significant but focal atypia
ULM is the most common gynecological tumor in women. In contrast, the incidence of
ULMS is very low, and in a preoperative diagnosis of ULM, ULMS is found in about
0.5% of cases (Hart, 2002). Since the malignant uterine smooth muscle tumors are rare,
the knowledge about the clinical behavior of these tumors is still somewhat limited and
as delineated above, certain definitions are still divergent (Table 8). Anyhow, the
direction during the years has been towards more stringent ULMS diagnosis criteria. In
Finnish population altogether six ULMS cases have been reported in the context of FH
germline mutation. Five of the ULMS patients are members of the HLRCC families
(FAM1, FAM4, FAM6; study I) and one was found in the screening of early-onset ULMSs
by Ylisaukko-oja and co-workers (2007a). Originally, in the case of the five ULMSs in the
Finnish HLRCC families, atypia or increased mitotic activity had been according to the
pathology reports (the number of mitotic figures rarely stated in the pathology reports)
interpreted as indicative for malignancy and had been reported to the Finnish Cancer
Registry as ULMSs. The ULMS diagnosis was assessed and confirmed from most of the
tumor specimens at the time when the patients were diagnosed as FH mutation carriers
(Launonen et al., 2001, Kiuru et al., 2002 & 2005, Ylisaukko-oja et al., 2006a).
Although the Finnish HLRCC families are clearly at a high risk of developing FH
mutation-associated malignancies seen as a high incidence of RCC, the complete lack of
ULMS cases in other populations has been somewhat surprising. Hence, we have now
re-evaluated the histology of five out of the six Finnish ULMS cases in light of the latest
World Health Organization (WHO) diagnosis guidelines (WHO Classification of Tumors
2003; Tumors of the Breast and Female Genital Organs). A tumor from the other ULMS
patient of FAM1 (from year 1966) was not available for re-evaluation. The remaining
four cases from the families were diagnosed between years 1975-1996. With the current
criteria, the four tumors were now considered by a pathologist as atypical or




No coagulative necrosis, no
or mild atypia 15
ULM






Some experts prefer designating tumors in
this category with >15 MF/10 HPF as
“a tumor of uncertain malignant potential”








Some experts prefer designating tumors in
this category with 2-9 MF/ 10 HPF at least
“a tumor of uncertain malignant potential”
(Miettinen & Fetch, 2006)
No coagulative necrosis,
diffuse and significant atypia 10 ULMS
Coagulative necrosis any ULMS
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the tumors were independently re-evaluated by two pathologists according to the
current guidelines, and still the interpretations varied in the case of one of the tumors as
being “an atypical ULM as worst” or “a borderline case”. True ULMSs are highly
malignant and recurrence is mostly detected within two years. Overall five-year survival
rates range from 15% to 25%, varying historically largely due to the use of different
criteria for their diagnosis (WHO Classification of Tumors 2003; Tumors of the Breast
and Female Genital Organs). No recurrence or metastases have been observed in the five
members of the families originally considered as affected with ULMS. All of the patients,
except one, were alive after several years (9, 25, 25 and, 28 years) from the point of ULMS
diagnosis (based on Cancer Registry data of year 2003). The patient from whom no
tumor block was available for re-evaluation died from the RCC. The sixth Finnish ULMS
patient with a germline FH mutation found in the screening of early-onset ULMSs died
of a metastatic disease 12 years after the diagnosis of the primary tumor (Ylisaukko-oja et
al., 2006a, Ylisaukko-oja, 2007). The histopathological features of the tumor were also
indicative for ULMS.
In conclusion, while the high relative risk obtained for ULMS is adequately determined
based on the Cancer Registry data, the true malignant potential of the uterine tumors in
HLRCC is likely to be much less dramatic. Of note, besides these four atypical ULMs,
five additional patients with atypical ULMs were identified in studies I and II.
Furthermore, two cases have been reported in North America in the context of HLRCC
(Toro et al., 2003). Interestingly, because atypia (or mitotic activity) is not that common in
ULMs in general (Docent J. Arola, personal communication), the unusual features in the
tumors seem to be indeed characteristic of HLRCC, as strongly suggested by our Cancer
Registry data analysis.
Since ULMSs are highly malignant, it is important to identify markers that would
facilitate the differentiating diagnosis of benign and malignant tumors. For this purpose,
the role of DNA ploidy, AgNOR counts, IHC for PCNA, MIB-1 (Ki-67), p53, estrogen
receptor (ER), progesterone receptor (PR), and ERBB2 has been studied in uterine tumors
(unrelated to HLRCC) (Layfield et al., 2000). The proposed indicators for ULMS, which
have consistently been seen in two independent studies, include increased MIB-1 and
p53 expression and loss of PR (Mittal & Demopoulos, 2001). Karyotypically ULMSs are
much more complex than ULMs and commonly no unifying aberrations have been
observed between these tumor types. However, recently, a set of cellular and atypical
ULMs were shown, similarly to ULMS, to display loss of the short arm of chromosome 1.
Hence, these variant types of ULMs were proposed to possibly represent a premalignant
stage and have an increased malignant potential (Hodge & Morton, 2007).
6.3. Role of hypoxia and genetic instability in TCA cycle-deficient
tumors (III)
Fast growing cancers are often deficient of oxygen and nutrients until the blood supply
is adjusted to the altered situation. Transcriptional adaptation to hypoxia is mediated by
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hypoxia-inducible factor HIF1, which drives e.g. the transcription of VEGF, thus
supporting the neovascularisation and blood supply of a tumor. Typical of cancer cells is
also genetic instability, which was recently suggested to result from hypoxia-caused
defects in mismatch (MMR) and recombinational (HR) genes (Mihaylova et al., 2003,
Koshiji et al., 2005, Shahrzad et al., 2005, Bindra et al., 2005a, Bindra & Glazer 2007a, see
also 2.1.2.4.). The MMR proteins that were proposed to be down-regulated by hypoxia
included, with some variability between studies, MLH1, PMS2, MSH2, and MSH6
(Mihaylova et al., 2003, Koshiji et al., 2005, Shahrzad et al., 2005). This evidence has led
us to hypothesize whether pseudohypoxia resulting from a deficient TCA cycle (Selak et
al., 2005, Isaacs et al., 2005, Pollard et al., 2005b) could cause genetic instability. Thus,
HLRCC and HPGL tumor material was studied for stabilization of HIF1  and down-
regulation of MMR as well as for microsatellite instability (MSI). Of the suggested MMR
proteins MSH2 was chosen for our study object. The previous data on the direct
association of HIF1  stabilization and MMR protein expression in clinical samples has
been obtained from sporadic CRC tumor material (Koshiji et al., 2005).
6.3.1. HIF1
In the studied samples, 67% and 79% of the HLRCC tumors and SDHB/C/D mutation-
associated PGLs, respectively, were found with a moderate or high level stabilization of
HIF1 . None of the PHEOs (including one SDHD tumor) showed stabilization of the
protein. An alternative pathway in the genesis of the remaining HIF1  negative
PGLs/PHEOs could have been the HIF1-independent nerve growth factor (NGF)
pathway. A defect in this route causes a failure in the developmental apoptosis of
neuronal precursor cells, thereby retaining cell populations with a neoplastic capability
(Lee et al., 2005, see also 2.4.).
Somewhat surprisingly, the majority (3/4, 75%) of the studied non-familial control ULMs
displayed also significant levels of HIF1 . In previous studies, HIF1  has been detected
with IHC strongly or moderately in HLRCC-associated RCCs and ULMs, respectively,
and altered levels of HIF1  targets (e.g. VEGF, TSP1, BNIP1) and increased microvessel
density have been seen in HLRCC-associated ULMs compared to sporadic ones (Pollard
et al., 2005a & 2005b). Previous data on HIF1  in sporadic ULMs, however, could not be
found. The number of control ULMs in our study was nonetheless quite small, and thus
no far-reaching conclusions can be drawn. Similarly in our study, many non-familial
PGLs (25/35, 71%) also showed stabilization of HIF1 . Some patients with apparently
sporadic PGLs have been shown to harbor germline mutations in SDHB or SDHD
(Neumann et al., 2002), but the non-familial PGLs on the tissue microarray (TMA) were
screened for SDHD mutations with negative results. A small number of non-familial
PGLs with up-regulated HIF1  could still be explained with an underlying germline
SDHB mutation, which has been seen in 6.4% of apparently sporadic PHEOs/PGLs
(Jimenez et al., 2006). Somatic mutations of SDHB have been suggested to also play a role
in the tumorigenesis of truly sporadic PHEOs/PGLs, but only one case has been reported
so far (van Nederveen et al., 2007). Of note, the carotid body, one of the most common
origins of a PGL tumor, is an oxygen sensing organ. Hyperplasia of the carotid body and
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a higher incidence of PGLs are more often seen in people living in high altitudes or
suffering from certain medical conditions resulting in hypoxemia, such as chronic
obstructive pulmonary disease (Saldana et al., 1973, Chedid & Jao, 1974, Pacheco-Ojeda
et al., 1988). Moreover, expression profiles of some sporadic PGLs/PHEOs have been
shown to display hypoxia markers similarly with VHL and SDHB/D tumors as well as
expression of angiogenic proteins, such as VEGF (Jyung et al., 2000, Salmenkivi et al.,
2003, Dahia et al., 2005). Hence, it is possible that the activation of HIF pathways due to
real hypoxia is associated with PGLs in general, thereby explaining the HIF1  protein in
the sporadic PGLs of our study. Of note, the response to hypoxic conditions and the
activation of hypoxia pathways due to genetic alterations are not mutually exclusive but
can in combination result in an enhanced hypoxia response (Semenza, 2003).
6.3.2. Mismatch repair and microsatellite instability
Despite the majority of the studied samples showing increased HIF1  levels, no MSI or
reduction of MSH2 protein was detected in any of the TCA cycle-deficient or non-
familial tumors. The presence of normal p53 has been suggested to be an essential factor
in the HIF1 -driven down-regulation of MSH2 and subsequent MSI (Koshiji et al., 2005,
To et al., 2005). Lack of p53, however, was not considered to be the cause of the negative
result of our study, since the majority of the HLRCC-associated RCCs had been analyzed
for p53 mutations and p53 protein expression revealing no abnormality. Studies showing
some association of increased immunoreactivity of p53 and/or p53 mutations with
tumorigenesis of (adrenal) PHEOs have been reported, mainly linking inactive p53 to the
malignant outcome of a tumor (Yoshimoto et al., 1998, de Krijger et al., 1999, Gupta et al.,
2000). In our study material, only three PGL tumors and none of PHEOs were malignant.
Moreover, another study excluded the involvement of p53 mutations in the
tumorigenesis of hereditary and sporadic PGLs. The results of the study showed an
increased immunoreactivity of p53 in ~35% of the studied specimens, including both
SDHD and sporadic tumors. The increased immunoreactivity of p53 is often seen in
tumors with a p53 mutation as the mutant p53 has a longer half-life. However, since no
p53 mutations were found in the tumors, the IHC result was suggested to be a
consequence of hypoxic induction of a wild-type p53 protein rather than stabilization of
a mutant p53 (van Nederveen et al., 2003). Thus, the lack of p53 as a cause of the absence
of defective MMR in HIF1 -positive PLGs can be excluded. The requirement of p53 for
the effect has anyhow become questionable, since the hypoxia induced repression of
MMR has also been seen in cell lines deficient for p53 (Bindra & Glazer, 2007a, Bindra et
al., 2007).
Previously, expression of MMR proteins and genetic instability has been examined in
sporadic tumors of the HLRCC and HPGL spectrum as well as PHEOs of a MEN2
background. In one study, benign MEN2A-associated PHEOs, and benign and malignant
sporadic PHEOs were assessed for the MSI analysis of intronic sequences in some tumor
suppressor genes (TSG; p53, RB, WT1, and NF1) as well as for sequence and IHC
analyses of MLH1 and MSH2 (Blanes et al., 2006). The results showed a lower incidence
of microsatellite lesions and down-regulation of MMR in locally invasive and benign
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tumors suggesting MSI to be mainly involved in the tumorigenesis of malignant PHEOs.
The association of hypoxia to the down-regulation of MMR was not witnessed in this
study since the reduction of the proteins was seen in the peripheral and not in the central
compartment of the tumors, in which hypoxia is more pronounced (Blanes et al., 2006).
Moreover, in another study of benign familial (including one SDHB tumor) and sporadic
PHEOs, the Bethesda MSI marker set showed no alterations in the studied microsatellites
(Namour et al., 2006). Similar studies on PGLs have not been reported. The few studies
on MSI in uterine tumors have shown instability in 30% ULMs (the number of
microsatellite lesions was not available) and low instability in 18% of ULMSs (in one out
of seven microsatellite markers) (French et al., 1998, Amant et al., 2001). In renal cancer,
repression of mainly MSH3 and MLH1 has been occasionally observed (Leach et al.,
2002, Deguchi et al., 2003). Some RCC cell lines seem to display MSI but renal tumors are
usually microsatellite stable (Diakoumis et al., 1998, Kanomata et al., 1998, Cullinane et
al., 2004). Thus, MSI and the down-regulation of MMR do not seem to be strongly
associated with the studied tumor types in general. As the inherited MMR defect and
predisposition to genetic instability leads to a restricted spectrum of tumors in HNPCC
(Sieber et al., 2005), some kind of tissue or cell type-specific factor may play a role in the
context of hypoxia-induced genetic instability as well.
The hypothesis of a HIF1  mediated effect of hypoxia on MSH2 function (Koshiji et al.,
2005) has served as a model for our study on the influence of HIF1  in TCA cycle-
deficient tumors. The study by Koshiji and co-workers suggested a mechanism in which
HIF1  displaces the transcriptional activator c-MYC from MSH2 promoter (Koshiji et al.,
2005). However, observations suggesting repression of MMR (both MSH2 and MLH1)
under hypoxia takes also place in the absence of HIF1  (in HIF1  deficient cells) have
recently gained evidence (Mihaylova et al., 2003, Bindra & Glazer, 2007a). In the light of
these results, the arrant HIF1  stabilization (pseudohypoxia) in the TCA cycle-deficient
tumors might not have been capable of resulting in down-regulation of MMR. However,
if postulating that the HIF1  observed in the non-familial PGLs could be due to real
hypoxia, down-regulation of the MMR system could actually have been seen in them.
Consequently, the presence of real hypoxia in the SDHB/C/D PGLs  must  also  be
considered. Although the recent evidence suggests co-repression of MSH2 and MLH1,
the role of MLH1 has now been highlighted since the decrease of the MLH1 protein
appears to be greater than that of MSH2 (Mihaylova et al., 2003, Bindra & Glazer, 2007a).
Although a possible reduction in the MLH1 protein was not assessed in our material,
absence of MSI in all the tumors was nevertheless evident.
The functional consequences of the hypoxia-driven MMR defect have been studied by
MSI analysis or by analyzing the mutation status of a reporter gene in cell lines cultured
in hypoxia (Mihaylova et al., 2003, Koshiji et al., 2005). Moreover, accumulation of K-ras
mutations has been observed in cells cultured under hypoxic conditions (Shahrzad et al.,
2005). Yet the in vivo evidence of the link between hypoxia, down-regulation of MMR,
and subsequent consequences has remained light. Bindra and co-workers discussed in
their recent review article the discrepancies between different studies related to the lack
of MLH1 reduction in one study by Koshiji and co-workers (2005) (Bindra et al., 2007). As
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a possible explanation was suggested the different levels of hypoxia used; 1.0% and
0.01% O2 in the study by Koshiji and co-workers (2005) and Mihaylova and co-workers
(2003), respectively, thus proposing that the repression of MLH1 requires more severe
hypoxia (Bindra et al., 2007). In normal tissue the oxygen tension varies being 50 mmHg
on average which corresponds to 7% of O2, whereas the mean tension of 10 mmHg
corresponding to 1.5% of O2 is seen in tumors. In a hypoxic tumor the tension can be zero
(Greijer et al., 2005). Hence, it seems that in vivo a tumor should be almost anoxic at least
to repress MLH1.
In conclusion, our results suggest that HIF1  is not sufficient to cause MSI and the
down-regulation of MSH2 in TCA cycle-deficient tumors and non-syndromic PGLs.
Therefore more data is required to determine the possible tissue specificity and other
factors mediating the hypoxic effect, the differences in the significance of different MMR
proteins, as well as the severity of hypoxia required for the repression of MMR,
especially in vivo.
6.4. Characteristics of the alternative transcript of FH (FHv) (IV)
The function of each protein takes place in a certain subcellular compartment or
compartments. This distribution is orchestrated by targeting signals (such as
mitochondrial, nuclear, endoplasmic reticulum), specific to each compartment, as part of
the protein peptides. The removal of the targeting signals is a mechanism to alter protein
localization or even function. The differentially distributed protein isoforms can be
encoded by different genes but can also be produced from a single gene by an alternative
transcription or translation initiation, splicing, or post-translational modification
(Danpure, 1995). The implication of these phenomena is the allowance of a greater
diversity of gene products without enlargement of the genome. The alternative forms
can be utilized in the regulation of protein function for example in the different stages of
development, different cells and tissues, and in the response to internal and external
signals.
6.4.1. Transcript and protein characteristics of FHv
FH operates in the mitochondrial TCA cycle and is targeted to the mitochondria by an
N-terminal targeting signal, encoded by exon 1. The variant transcript of FH (FHv), part
of which was originally described in the Aceview database, was found to contain exons
2-10 identical to FH and an alternative first exon (1b). The exon 1b of 245 bp in length
mapped to the sequence of FH intron 1-2. The transcript was postulated to be produced
by an alternative promoter, but no sequence suggestive of a core promoter in the 1b and
near flanking sequences, however, could be found with in silico tools. Nonetheless, the
existence of a further localizing promoter cannot be excluded. The alternative promoter
usage results in transcripts with differing N-terminal parts, either varying only in the 5’
UTR or also at the protein level (Landry et al., 2003, Hughes, 2006). In the case of FH, the
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protein produced from the alternative transcript is different as it lacks exon 1 and is thus
devoid of the mitochondrial targeting signal.
The eucaryotic mRNAs, in most cases, are translated from the first ATG (AUG) at the 5’
end of the mRNA. This is based on the scanning model which postulates that the 40S
ribosomal subunit runs along the 5’ end of the mRNA until it reaches the first ATG
(Kozak, 1995). The translation of FHv was studied with an overexpression construct
which revealed in an immunoblotting three peptides of a closely same size. Exon 1b does
not contain any ATGs that function as translation initiation codons but two CTGs
(CUGs) which also can serve as initiation sites (Packham et al., 1997, Meiron et al., 2001).
The subsequent first three ATGs are located in the following exons: two in exon 2, and
one in exon 3. Mutating the CTGs and ATGs one by one, the three peptides were found
to  be  produced  from the  ATGs  in  exons  2  and  3,  and  exon  1b  thus  to  be  5’  UTR.  The
predicted sizes of the peptides were 46.4, 45.2, and 41.7 kDa, the middle one seen to be
produced most inadequately (in comparison, processed FH without the signal peptide is
50.2 kDa). Whether the initiation from multiple ATGs is an artifact or rational
phenomenon is not known, but may be due to leaky ribosomal scanning (LRS). For
efficient translation, an optimal sequence flanking an ATG is 5’-CCA/GCCATGG-3’ of
which a purine at the position -3 and G at the position +4 are the most important ones
(Kozak, 1987). It has been shown that if the sequence surrounding the first ATG is
compromised, LRS can occur leading to translation from both the imperfect first codon
and additional downstream ATG(s) (Smith et al., 2005). In FHv, the second ATG in exon
2 (“ATG2”) lacks an optimal flanking sequence whereas the first ATG in the exon 2
(“ATG1”) and the first ATG in exon 3 (“ATG3”) display a relatively favorable sequence
context (nucleotide A at the positions -3 and +4, representing the third common flanking
sequences of a functional initiator) (Kozak, 1987) (Figure 5). In addition to the poor ATG
context, short and GC rich 5’ UTR, and downstream secondary structure have been
suggested to lead to LRS. Close adherence of the ATGs also has a strong influence but
even 100 nucleotides spacing is possible (Kozak, 1991 & 1995). However, whether lack of
G in the position +4 of the “ATG1” and quite close adherence of the ATGs could cause
LRS and the translation also from the downstream initiators remains to be determined.
Interestingly, when the subcellular distribution of FHv was studied, the GFP-tagged FHv
protein(s) were found to target the nucleus and cytosol. As expected, FH, both
endogenously and as GFP-tagged was observed mainly in the mitochondria and to a
lesser extent in the cytosol. No nuclear targeting signal in FHv was found with in silico
modeling, but alternatively the nuclear localization can sometimes be determined by a
post-translational glycosylation of the peptide (Rondanino et al., 2003, Guinez et al.,
2004). The localization to the nucleus seemed to be specific to FHv since the protein
produced  from  the  cDNA  construct  of FH exons 2-10 (artificial ATG as an initiator)
(FHno-signal) remained in the cytosol. Moreover, the nuclear distribution of FH has also
been seen in a previous study on endogenous fumarase of rat (Bowes et al., 2007). The
cytosol is the “default” location of any protein and therefore it is not sure whether the
putative FHv targeting signal to the nucleus is somehow inadequate to transfer all the
protein or whether the FHv could also have a function in the cytosol. No difference in
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the distribution was observed when translation from the three ATGs was inhibited in
turn. In general, the extra-mitochondrial distribution of primarily mitochondrial proteins
is not uncommon (Mueller et al., 2004).
The overexpression of FHv in cells showed no increase in FH enzyme activity. The FHv
peptide lacks at least 32 N-terminal amino acids that are present in the processed
(mature) FH. These amino acids may be essential for formation of the FH tetramer or
catalytic capability of the protein, or both. The function of FHv, however, may be
completely different from that of FH, and the enzymatic activity is thus unnecessary.
6.4.2. mRNA expression of FHv
The translation of FHv was studied with overexpression constructs since an FHv-specific
antibody was not available for immunoblotting and immunofluorescence analyses. Some
endogenous bands in addition to FH (~50 kDa) were detected in the FH immunoblotting
of cell lines but evidence that some of those would have represented the endogenous
FHv could not be obtained. mRNA expression, however, was analyzed from human
tissue cDNA panels and different (mainly cancer) cell lines. FHv was ubiquitously
expressed in the tissues and cell lines studied. The expression of FHv was evident both in
the fetal and adult tissues but was somewhat lower (as was of FH) in fetal tissues. This
suggests FHv is not specifically involved in developmental processes as sometimes is the
case in the usage of alternative transcripts (Ayoubi & van de Ven, 1996). However, the
expression of FHv was hundreds of times lower compared to FH. Alternative promoters
or splicing can also be utilized when a tissue specific expression or response to a certain
external stimulus is required (Ayoubi & van de Ven, 1996). Since cellular stresses have
been shown to induce, for example, alternative splicing of several genes (e.g. VEGF and
COX1), the induction of FHv was tested in various stress conditions. Neither glucose nor
serum deprivation, nor hydrogen peroxide had any effect on FHv expression; nor did
short-term hypoxia. When hypoxic (1% O2) exposure was prolonged to 72-96 hours, an
increase in FHv expression was noted in several cell lines (9 out of 15). The most evident
response (a four-fold increase) was observed in a uterine leiomyosarcoma cell line
(HTB115) suggestive of some cell or tumor type specificity in the expression of FHv.
Subsequently the stress treatment range for this cell line was extended to heat exposure
(42°C) which resulted in a gradual nine-fold increase in FHv in two hours compared to
the untreated control cells. No major changes were observed in the expression of FH in
either condition, although down-regulation of this factor central to aerobic metabolism
could have been conceivable.
An elevated temperature, causing acute or chronic stress in cells, can induce the so-called
heat shock response, which includes activation of heat shock factors (HSFs). HSFs drive
the transcription and synthesis of proteins of the heat shock family (HSPs), as well as
several other proteins (Pirkkala et al., 2001, Sonna et al., 2002, Baird et al., 2006). HSPs are
involved in the folding of proteins, regulation of the cellular redox state, and in protein
turnover, events which are related to the survival of the cell or induction of apoptosis if
the stress becomes too severe (Sonna et al., 2002). In addition to heat, hypoxia is also
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known to result in the heat shock response, as in the case of induction of HSP70 and
downstream pathways in chronic hypoxia (Fei et al., 2007). Moreover, hypoxia-induced
HIF1 has been shown to regulate HSF and activate the heat shock pathway (Baird et al.,
2006). On the other hand, heat induction of HIF1  has been suggested to be mediated by
HSP90 (Katschinski et al., 2002). Heat and hypoxia pathways are thus connected. Our
results suggest that FHv could be regulated by stress-induced factors and be related to,
for example, stress-induced apoptosis. Long-term hypoxia especially was detrimental to
the cells and some differences in the appearance (rounding, detaching from surface)
between the studied cell lines was seen, though no clear correlation between the
condition of the cells and the increase in FHv could be observed. Alternatively, FHv
could play a part in the adaptation of a cell to a disadvantageous environment or have a
role in anaerobic metabolism, for example. However, no evidence of heat shock (HSE) or
hypoxia response elements (HRE) for HSF/HIF binding in FHv could be found with in
silico tools. Interestingly, the rarer HSF1 function as a negative regulator of the RAS
pathway does not necessitate actual binding to the DNA sequence (Chen et al., 1997).
Moreover, at least in the case of hypoxia response, a variety of transcription factors other
than HIF (e.g. NF B and p53) are activated. The activation of different pathways in
hypoxia is probably cell type-specific and dependent on the degree and length of the
hypoxia (Cummins & Taylor, 2005).
In conclusion, the differential subcellular distribution and the lack of FH enzyme activity
strongly suggest that FHv has a role distinct from the TCA cycle. The hypotheses of the
function of FHv in the response to hypoxia and elevated temperature are tempting,
although regulatory elements required for at least HIF or HSF binding were not found in
the FHv sequence. Whether stabilization of HIF1  in FH-deficient tumors could enhance
transcription of FHv is an intriguing idea as well. Somewhat disturbingly, mRNA
expression of FHv was clearly lower compared to FH, and the endogenous FHv protein
could not be verified with our analyses. Notable is that FH is one the most essential
proteins needed in a cell and therefore transcribed and translated efficiently, thus
proving a challenging comparison point. The FHv transcript was originally derived from
ovarian tissue, which was not included in the cDNA tissue panel analyzed for FHv
expression. Whether expression of FHv would be significantly higher in ovarian tissue
than in the studied tissues remains to be determined. There are examples of tissue-
specific alternative promoter usage, e.g. the 100-fold lower expression of -amylase in
the liver compared to the parotid gland (in this case, the alternative promoter produces
transcripts differing only by the 5’ UTR) (Shibler et al., 1983). Low expression of certain
regulatory transcripts may indeed be expedient as it may be critical that their
transcription and translation is kept at a low level (Wera et al., 1995, Kozak, 1996).
Moreover, the existence of a similar, alternative exon 1 in the tumor suppressor SDHB
supports the relevance of the variant FH transcript. Anyhow, hypotheses on function of
FHv still need to be verified.
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7. CONCLUSIONS AND FUTURE PROSPECTS
To clarify the clinical characteristics in FH germline mutation carriers, Finnish
HLRCC/FHD families were broadly examined for the associated tumors and analyzed
for cancer risk. The Cancer Registry risk analysis provided for the first time calculated
risk values for renal cell cancer (RCC) and uterine leiomyosarcoma (ULMS). The analysis
estimated the risk (standardized incidence ratio) in association of HLRCC/FHD to be 6.5-
and 71-fold for RCC and ULMS, respectively, compared to that of the general
population. In young individuals the risk was even more pronounced. However, if the
most recent - more stringent - classification for ULMS is applied, it now seems likely that
the patients with an FH mutation are prone to develop atypical or proliferative ULMs
(with a low risk of recurrence), and formation of ULMS as currently defined is
uncommon. Naturally, the risk estimate for RCC only reflects that of other populations.
As a novel finding, the loss of FH was shown to possibly be involved in the genesis of
breast and bladder cancer, though increased incidence of these tumors could not be
proven with the Cancer Registry risk analysis. Moreover, kidney cysts were frequently
detected in young FH mutation carriers. In the context of FH deficiency were for the first
time observed malignant manifestations. The Spanish RCC case showed that the
HLRCC-associated renal tumors can also include conventional (clear cell) type RCC. This
data points to the possibility of FH mutation carriers among young patients with
conventional cancer when other genetic factors (e.g. VHL mutation) do not seem to play
a role. In these cases, a simple diagnosis method could be FH immunohistochemistry.
To clarify the molecular pathways in association of FH and SDH defects, the hypothesis
of the role of hypoxia/HIF1 -induced repression of mismatch repair (MMR) was
analyzed in HLRCC and HPGL tumor material. The analysis confirmed previous
observations of HIF1  stabilization in these tumors. Increased HIF1  seen also in some
sporadic paragangliomas (PGL) probably results from real hypoxia present in PGLs in
general. However, any of the tumors displayed no repression of mismatch repair protein
MSH2 or increased MSI. Thus, our results showed that at least HIF1  alone is not
sufficient for causing MSI in these tumors and more data is required to determine the
other required components as well as the implication of the pathway in vivo. The
alternative transcript of FH (FHv) was found to contain instead of exon 1, an alternative
exon 1b, which seemed to remain untranslated. Differential subcellular distribution, lack
of FH enzyme activity, low mRNA expression compared to FH, and induction by cellular
stress suggest that FHv has a role distinct from FH, for example in apoptosis or survival.
However, the endogenous protein expression as well as the physiological significance of
the variant requires further elucidation.
In summary, these studies suggested the association of novel tumor types and subtypes
with loss of FH. The dynamic accumulation of the new data from clinical follow-up and
genetic studies provides essential updates to the characteristics, classification, and
prognosis of tumors. Awareness of these changes in the collection and analysis of tumor
material for research purposes is also an important issue that has emerged from this
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study. The evidence of inhibition of PHDs, factors of the degradation machinery of
HIF1 /HIF2 , and up-regulation of the hypoxia pathway target genes by succinate and
fumarate is strong. The actual implication of the stabilization of HIF1  on TCA cycle
associated tumorigenesis is, however, still under investigation. The results presented
here suggest that the putative tumorigenic effect of HIF1  in TCA cycle-deficient tumors
does not involve increased genetic instability. Physiological significance of the
alternative transcript of FH (FHv) remains obscure, but as being responsive to cellular
stresses it would be intriguing to consider it operating in some tumorigenesis-associated
pathway.
In the future, the research on TCA cycle-associated tumorigenesis will undoubtedly
continue to elucidate the functional consequences of the loss of FH and SDH as well as
search for possible therapeutics. Introduction of -ketoglutarate derivatives has
successfully been shown to restore normal PHD activity in FH- and SDH-deficient cells,
suggesting a therapy possibility for the cancers associated with TCA cycle dysfunction
(MacKenzie et al, 2007). Alternatively, since the energy production in TCA cycle-
deficient cells seems to be dependent on the anaerobic pathways, inhibitors of glycolysis
enzymes have been proposed as putative therapeutics agents. Weak inhibitors would
minimally harm aerobic tissues but the tumor tissue dependent on glycolysis would be
more severely affected (Catherino et al., 2007). A valuable model for testing the future
drugs will be the recently developed kidney-specific Fh1 knock-out mouse (Pollard et al.,
2007). In general, advanced RCC has a limited response to drug treatments. The novel
targeted therapies for RCC include molecules sorafenib and sunitinib which are broad-
spectrum inhibitors of RTKs activated by HIF targets such as VEGF, PDGF, and TGF
(Grandinetti & Goldspiel, 2007). Thus, these novel therapeutic agents may also provide
an alternative for the growth suppression of HLRCC renal tumors with an overactive
HIF pathway.
Since HLRCC is a quite newly identified and rare syndrome, any international consensus
on the patient surveillance has not yet been established. Only some provisional
recommendations have been presented based on the present knowledge about the
clinical outcome of HLRCC (Pithupakorn & Toro, 2006; http://www.geneclinics.org). The
surveillance guidelines applied to Finnish HLRCC patients at present include the follow-
up of uterine tumor formation and progression by gynecological examination and
ultrasound annually to every two years (Dr K. Aittomäki, personal communication).
Since RCCs in HLRCC seem to have a very aggressive nature, the frequent, at least
biannual, screening of the kidneys is specifically emphasized. As being sensitive and
safe, a contrast enhanced MRI is recommended as the primary method (Kujala et al.,
2007; http://www.uroweb.org/publications/eau-abstracts-online/?AID=14154). However,
to reach a comprehensive consensus for HLRCC patient surveillance practices, a more
long-term experience is required.
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FH mutation carriers of the Finnish HLRCC families and the FHD family. Number of all family















M1 F Leiomyomas (44)
M2 F Leiomyomas (34) Breast cancer (53)
M4 F Yes Leiomyomas (39)
(atypical)







M7 F Leiomyomas (29) Yes (42) Yes
M9 M (-57)
M13 F Yes Yes (33)
M16 F Yes Leiomyomas (33)
M17 F Leiomyomas (39) Yes (39)
M18 F Leiomyomas (37) Cancer of unknown origin (42)
M19 F Leiomyosarcoma (35)** Yes (35)
M24 F Leiomyoma (25)
M25 M Yes
M26 F Leiomyomas (44)




B1 F Yes (33) Yes
B2 M Yes (26)
B3 F Leiomyomas (32) Chronic lymphatic leukemia (48)
Adrenal gland adenoma (40)
B5 M Prostate cancer (63)Adrenal gland adenoma (65)
B6 F (-85)
B7 F Leiomyomas (40) Yes





C4 F (-74) Yes
C5 F Yes Leiomyomas (34) (atypia) Yes (35) Yes
C6 M Yes
88
C8 F Yes Leiomyomas (27) (atypia)








D3 M Yes Hodgkin’s lymphoma (25)
D5 M Salivary gland adenoma (54)
D6 F Leiomyomas Fibrocystic lesions of the breast





D0*** F Leiomyoma (36) (atypia)
FAM5 (37)
E1 F Yes (30) Leiomyoma (45) Yes (50) Yes
E2 F Yes (39) Leiomyomas (37) Yes (36)
E3 M Yes (71) Yes
E4 M (-51) Yes
E7 M Yes Esophagus cancer (53)
E11 F Yes (90) Basal cell cancer (83)
E12*** F Liver/bile duct cancer (82)
FAM6 (42)
F1 F Leiomyosarcoma (32) /
atypical/proliferative ULM**
FAM 7 (6)




G3 M Yes Bladder cancer (71)
G5 M Basal cell cancer (70)
G6 F Breast cancer (50)
Total of mutation carriers
identified / total of family
members identified
54/868
ULM; uterine leiomyoma. *In parenthesis the year of birth of unaffected (CLM/ULM/RCC) individuals. **Tumors
originally diagnosed as uterine leiomyosarcomas agree the most recent diagnosis criteria of atypical ULMs. Some
tumors displayed in addition increased proliferation (mitotic activity). Tumor from patient M19 was not re-
evaluated. ****Obligate FH mutation carrier. ****FH deficiency family. Homozygous carriers are not listed. Tumor
names in bold indicate biallelic inactivation of FH in the tumor tissue (see also Tables 3 and 5).
